<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?OLF?><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Pharm Sin B</journal-id><journal-id journal-id-type="iso-abbrev">Acta Pharm Sin B</journal-id><journal-title-group><journal-title>Acta Pharmaceutica Sinica. B</journal-title></journal-title-group><issn pub-type="ppub">2211-3835</issn><issn pub-type="epub">2211-3843</issn><publisher><publisher-name>Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7260574</article-id><article-id pub-id-type="publisher-id">S2211-3835(20)30591-8</article-id><article-id pub-id-type="doi">10.1016/j.apsb.2020.05.009</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>He</surname><given-names>Chunting</given-names></name></contrib><contrib contrib-type="author" id="au2"><name><surname>Qin</surname><given-names>Ming</given-names></name></contrib><contrib contrib-type="author" id="au3"><name><surname>Sun</surname><given-names>Xun</given-names></name><email>sunxun@scu.edu.cn</email><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1">Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. . <email>sunxun@scu.edu.cn</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>30</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="epub"><day>30</day><month>5</month><year>2020</year></pub-date><history><date date-type="received"><day>5</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>18</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>Coronaviruses (CoVs) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) has caused major public health crises. There have been more than 4,400,000 reported cases of COVID-2019 and more than 300,000 reported deaths to date (16/05/2020). SARS-CoV, MERS-CoV and SARS-CoV-2 have attracted widespread global attention due to their high infectivity and pathogenicity. To date, there is no specific treatment proven effective against these viral infectious diseases. Vaccination is considered one of the most effective strategies to prevent viral infections. Therefore, the development of effective vaccines against highly pathogenic coronaviruses is essential. In this review, we will briefly describe coronavirus vaccine design targets, summarize recent advances in the development of coronavirus vaccines, and highlight current adjuvants for improving the efficacy of coronavirus vaccines.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p>Vaccination is the most effective and economical way to prevent viral infections. This review describes coronavirus vaccine design targets, summarizes recent advances and potential strategies for coronavirus vaccine development, and highlights promising technological routes and adjuvants for improving the effectiveness of coronavirus vaccines.<fig id="undfig1" position="anchor"><alt-text id="alttext0010">Image 1</alt-text><graphic xlink:href="fx1_lrg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Coronaviruses</kwd><kwd>SARS-CoV</kwd><kwd>MERS-CoV</kwd><kwd>SARS-CoV-2</kwd><kwd>Vaccine</kwd><kwd>Adjuvant</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">In 2019, a novel strain of coronavirus was found in humans<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref>. On February 11, 2020, WHO announced a new name for the epidemic disease: Corona Virus Disease (COVID-19). Meanwhile, the International Committee on Taxonomy of Viruses named the novel coronavirus as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As of May 16th, 2020, the epidemic of COVID-19 has caused more than 4,400,000 laboratory-confirmed cases and more than 300,000 reported deaths<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref>.</p><p id="p0015">COVID-19 is the third known zoonotic coronavirus disease<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> after Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). SARS is a zoonosis caused by SARS-CoV, which has infected 8096 humans, including 774 deaths (mortality rate 9.6%), in at least 29 countries<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref>. Another highly pathogenic coronavirus, MERS-CoV, has been reported in 27 countries with reported viral infection and 858 associated deaths (mortality rate 34.4%).<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Research indicates that SARS-CoV was transmitted from civet cats to humans and MERS-CoV was transmitted from dromedary camels to humans. However, the intermediate host of SARS-CoV-2 has not been identified<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>.</p><p id="p0020">SARS-CoV-2, together with SARS-CoV and MERS-CoV, has posed significant threats to international health due to theirs high pathogenicity and infectivity. Vaccination is an important strategy to provide protection from infectious diseases. However, to date, no vaccine has been approved to prevent coronavirus infection, indicating the need for further development of novel and effective vaccines against coronavirus infection.</p><p id="p0025">In this review, we will illustrate vaccine design targets, review current advances and potential strategies for vaccine development based on the spike (S) protein of SARS-CoV and MERS-CoV, and focus on how to improve the efficacy of vaccines through adjuvant formulations. Overall, these strategies may provide useful guidance for vaccine development of SARS-CoV-2.</p></sec><sec id="sec2"><label>2</label><title>Spike protein: a key target for coronaviruses vaccine</title><p id="p0030">Coronaviruses are widespread in nature. It can cause respiratory and intestinal infections in animals and humans. According to the phylogenetic relationships, coronavirus can be divided into four genera: Alpha, Beta, Gamma and Delta. Alpha and beta genera can infect mammals, while gamma and delta genera are mostly avian coronaviruses<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref>. There are seven known coronavirus that can infect humans: 229E, OC43, NL63, HKU1, SARS-CoV, MERS-CoV and SARS-CoV-2. The first four viruses cause only mild minor respiratory illness. The other three strains&#x02014;SARS-CoV, MERS-CoV and SARS-CoV-2&#x02014;are zoonotic and lead to severe respiratory syndrome<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>.</p><p id="p0035">Coronaviruses are the largest single positive-strand RNA viruses with a genome of 27&#x02012;32 kb<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref>. It is named for its corona-like appearance (<xref rid="fig1" ref-type="fig">Fig. 1</xref>
A). The virus genome mainly encodes four structural proteins: spike (S), nucleocapsid (N), membrane (M), envelope (E) proteins. S protein forms the spikes on the surface of coronaviruses and mediates adsorption and fusion of the virus and host cells. N protein forms a helical capsid, which locates inside the viral membrane to protect viral RNA. M and E proteins are important components of the viral envelope, and together mediate the assembly process of the virus<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref>. Among the four structural proteins, S protein is the leading mediator of virus entry and is the main factor that determines the virulence and host range of the virus.<fig id="fig1"><label>Figure 1</label><caption><p>Coronavirus and spike protein (S) structures. (A) Schematic structure of coronavirus and its key structural proteins, including spike (S), nucleocapsid (N), membrane (M), envelope (E) proteins. (B) Schematic structure of coronavirus S protein and its functional regions. S protein is composed of S1 and S2 subunits. SP, signal peptide. RBD, receptor-binding domain. RBM, receptor-binding motif. FP, fusion peptide. HR1 and HR2, heptad repeat 1 and 2 regions. TM, transmembrane. CP, cytoplasmic tail.</p></caption><alt-text id="alttext0015">Figure 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0040">SARS-CoV, MERS-CoV, and SARS-CoV-2 have strong human-to-human characteristics, which is attributed to the interaction between S protein and host cell surface receptors. SARS-CoV and SARS-CoV-2 use the angiotensin-converting enzyme 2 (ACE2) as a receptor<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref>
<sup>,</sup>
<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref>, whereas MERS-CoV uses dipeptidyl peptidase 4 (DPP4; also known as CD26) as a receptor<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref>. The distribution of receptors in humans and their affinity with S proteins determine the extent of tissue tropism and the intensity of transmission of coronavirus. The epidemiology and biological characteristics of SARS-CoV, MERS-CoV and SARS-CoV-2 are summarized in <xref rid="tbl1" ref-type="table">Table 1</xref>
<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>
<sup>,</sup>
<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref>
<sup>,</sup>
<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Epidemiology and biological characteristics of SARS-CoV, MERS-CoV and SARS-CoV-2, as of 16 May 2020.</p></caption><alt-text id="alttext0040">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Characteristic</th><th>SASR-CoV</th><th>MERS-CoV</th><th>SARS-CoV-2</th></tr></thead><tbody><tr><td rowspan="5">Clinical epidemiology</td><td>Total global number</td><td>8096</td><td>2494</td><td>4,434,653</td></tr><tr><td>Number of deaths</td><td>774</td><td>858</td><td>302,169</td></tr><tr><td>Mortality</td><td>9.6%</td><td>34.4%</td><td>6.8%</td></tr><tr><td>Affected countries</td><td>29</td><td>27</td><td>216</td></tr><tr><td>Transmission region</td><td>Globally</td><td>Regionally</td><td>Globally</td></tr><tr><td colspan="2">The predominant cell receptor</td><td>Human angiotensin-converting enzyme 2 (ACE2)</td><td>Human dipeptidyl peptidase 4 (DPP4 or CD26)</td><td>Human angiotensin-converting enzyme 2 (ACE2)</td></tr><tr><td colspan="2">Receptor binding affinity</td><td>High</td><td>High</td><td>Higher than SARS-CoV</td></tr><tr><td colspan="2">Pathogenic&#x000a0;mechanism</td><td>Primarily infects ciliated bronchial epithelial cells and type II pneumocytes, resulting in massive viral replication and cell damage</td><td>Primarily infects unciliated bronchial epithelial cells and type II pneumocytes, resulting in massive viral replication and cell damage</td><td>Primarily infects ciliated bronchial epithelial cells and type II pneumocytes, resulting in massive viral replication and cell damage</td></tr></tbody></table></table-wrap></p><p id="p0045">S protein is a large type I transmembrane glycoprotein whose trimers constitute the spike structure on the surface of the virus. The S protein (<xref rid="fig1" ref-type="fig">Fig. 1</xref>B) can be divided into two functional subunits: an N-terminal S1 domain contains signal peptide and receptor binding domain (RBD), and a C-terminal S2 domain contains fusion peptide and two heptapeptide repeats (HR1 and HR2) to facilitate viral fusion. RBD mediates the binding of virus and cell receptor, which then triggers a conformational change of the S protein, exposing HR1 and HR2 to form a 6-helix bundle fusion core structure, further leading to membrane fusion and viral RNA release<xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>. Furthermore, S protein carries B-cell epitopes, which induces the body to produce neutralizing antibody and provides immune protection<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref>. Because the S protein is involved in viral infection and is responsible for inducing host immune response and virus-neutralizing antibodies, it has been considered a key target for vaccine design.</p><p id="p0050">Antigen-specific targets of S protein include full-length S protein, S1 subunits, RBD and S2 subunits. Viral vector vaccines encoding full-length S protein or S1 subunits have been demonstrated to induce high levels of neutralizing antibodies in various animal models<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref>
<sup>,</sup>
<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref>. However, some non-neutralizing epitopes on full-length S protein or S1 subunits may compete with neutralizing epitopes, leading to several safety concerns, including inflammatory and immunopathological effects such as pulmonary eosinophilic infiltration and antibody-dependent enhancement (ADE) following subsequent viral challenge of vaccinated animals<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref>
<sup>,</sup>
<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref>
<sup>,</sup>
<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref>. ADE is a phenomenon in which non-neutralizing antibodies are produced following an infection or a vaccination leads to enhanced infection<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref>. One approach to mitigate the adverse effects of ADE is to narrow the immune response to target only critical or beneficial epitopes<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref>. Vaccines based on RBD elicited a robust protective immune response and neutralizing antibodies. At the same time, RBD does not contain non-neutralizing epitopes that may cause harmful immune responses, which is a hot spot for CoV vaccine development. It is worth mentioning that RBD has relatively low immunogenicity and often requires repeated doses and adjuvants<xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>. Because the S2 subunit is highly conserved and not prone to mutation, S2 region has become an important target for the development of protective vaccines. However, reports regarding the presence of neutralizing epitopes in S2 and a protective role for antibodies to S2 have been inconsistent. Several studies demonstrated that S2 domain could induce specific cellular immune response and a high level of total IgG but little neutralizing antibodies against coronavirus infection<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref>
<sup>,</sup>
<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref>. On the contrary, there are also reports that showed that S2 domain contains neutralizing epitopes and could induce neutralizing antibodies<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref>
<sup>,</sup>
<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref>.</p><p id="p0055">N protein serves multiple functions in viral replication, transcription, and assembly of the viral genome complex, which is more conservative than other proteins, such as S and M. Therefore, N protein has been also widely reported as a target antigen. N proteins have been shown to be highly immunogenic and capable of triggering T cell responses<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref>. Remarkably, many studies indicated that the serum containing anti-N protein does not contain neutralizing antibodies against coronavirus infection<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref>
<sup>,</sup>
<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref>. In addition, vaccines based on N protein not only failed to protect from homologous or heterologous challenge, but resulted in enhanced immunopathology with eosinophilic infiltrates within the lungs of SARS-CoV-challenged mice<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref>
<sup>.</sup>
</p></sec><sec id="sec3"><label>3</label><title>Advances in the development of SARS-CoV vaccines and MERS-CoV vaccines</title><p id="p0060">It is critical for CoV vaccines to induce robust humoral and cellular immunities. Previous studies indicated that the level of serum neutralizing antibody is correlated inversely with virus titers in the lungs, which effectively increased the survival rate of the vaccine host<xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>. Production of high titer neutralizing antibodies can block MERS-CoV replication in the lungs of vaccinated mice (<xref rid="fig2" ref-type="fig">Fig. 2</xref>
), confirming the importance of neutralizing antibody in fighting virus infection<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>. Similarly, the importance of T-cell responses against CoV infections was also highlighted in many studies<xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>. For example, depletion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in mice prior to challenge by SARS-CoV resulted in decreased survival rates to 35% and 45%, respectively (<xref rid="fig3" ref-type="fig">Fig. 3</xref>
)<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref>. Interestingly, virus-specific memory T cells but not neutralizing antibodies could be detected 6 years after infection in SARS survivors, suggesting memory T cell responses may provide broad and long-term protection against SARS-CoV infection<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref>. In general, both neutralizing antibody levels and T cell responses should be considered in current CoV vaccination strategies.<fig id="fig2"><label>Figure 2</label><caption><p>Vaccination of MERS S nanoparticle plus Matrix M1 protects mice from MERS-CoV challenge. (A) neutralizing antibody levels against infections of live MERS-CoV. GMT &#x000b1; standard deviation is graphed for each group of 10 mice. Dots represent individual mice. <sup>&#x02217;</sup><italic>P</italic>&#x0003c;0.05, <sup>&#x02217;&#x02217;&#x02217;</sup><italic>P</italic>&#x0003c;0.001, ns means not significant. (B) Lung MERS-CoV replication was determined by plaque assay. (C) MERS-CoV specific Leader mRNA expression (D) MERS-CoV genomic RNA expression. Mean &#x000b1; standard deviation are graphed for each group of 10 mice. Dots represent individual mice. LOD means limit of detection. <sup>&#x02217;&#x02217;&#x02217;</sup><italic>P</italic>&#x0003c;0.001. The figure was adapted with permission from Ref. 42. Copyright &#x000a9;2017 Elsevier.</p></caption><alt-text id="alttext0020">Figure 2</alt-text><graphic xlink:href="gr2_lrg"/></fig><fig id="fig3"><label>Figure 3</label><caption><p>Airway T cells are protective against SARS-CoV challenge. (A) Survival rate of SARS-CoV infected mice after depletion of airway CD4<sup>+</sup> T cells. <italic>n</italic>=5, rIgG i.n.; <italic>n</italic>=24, aCD4 i.n. (B) Virus titers of SARS-CoV infected mice after depletion of airway CD4<sup>+</sup> T cells. Titers are expressed as PFU/g tissue. <italic>n</italic>=3 mice/group/time point. *<italic>P</italic>&#x0003c;0.05. Data are representative of two independent experiments. (C) Survival rate of SARS-CoV infected mice after depletion of airway CD8<sup>+</sup> T cells. <italic>n</italic>=5, rIgG i.p.; <italic>n</italic>=7, aCD8 i.p. (D) Virus titers of SARS-CoV infected mice after depletion of airway CD8<sup>+</sup> T cells. <italic>n</italic>=3 mice/group/time point. <sup>&#x02217;</sup><italic>P</italic>&#x0003c;0.05. Data are representative of two independent experiments. The figure was adapted with permission from ref. 45. Copyright &#x000a9; 2016 Elsevier.</p></caption><alt-text id="alttext0025">Figure 3</alt-text><graphic xlink:href="gr3_lrg"/></fig></p><p id="p0065">No CoV vaccine is currently approved for use in humans. Most of the currently developed CoV vaccines are in the preclinical stage. In addition to the traditional inactivated and attenuated live vaccines, other development of candidate CoV vaccines was mainly focused on the S protein of coronaviruses. These types of S protein-based vaccines include nucleic acid-, viral vector-, virus-like particle (VLPs) and subunit vaccines. Because the research of SARS-CoV-2 vaccine is still in the early stages, the following review will discuss strategies for the development of SARS-CoV and MERS-CoV vaccines in the hope of providing useful guidance for the development of SARS-CoV-2 vaccines.</p><sec id="sec3.1"><label>3.1</label><title>Inactivated and live-attenuated virus vaccines</title><p id="p0070">SARS or MERS inactivated by physical (ultraviolet or radiation) or chemical (methanol, <italic>&#x003b2;</italic>-propiolactone and formalin) methods has been shown to cause high levels of neutralizing antibodies and protective immunity in several animal models including mice, rabbit and ferret<xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>. However, eosinophil infiltration in the lungs of animals vaccinated with inactivated SARS-CoV vaccine or MERS-CoV vaccine has raised concerns about the safety and ultimate protective efficacy of inactivated vaccine<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref>
<sup>,</sup>
<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref>. In addition, a double-inactivated SARS-CoV (doubly inactivated by formalin and UV irradiation) vaccine provides poor protection against lethal disease in aged-animal models following heterologous challenge<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref>. This result may be attributed to respiratory dendritic cells (rDCs) migration to draining lymph nodes (DLNs) progressively decreases as mice age, decreases in virus-specific CD8<sup>+</sup> T cell responses in lungs and more severe disease in older mice infected with SARS-CoV<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref>
<sup>,</sup>
<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref>. Based on the above results, candidate vaccines against emerging coronaviruses should emphasize the efficacy in older animal with virus infection.</p><p id="p0075">The live-attenuated virus vaccine, composed of recombinant SARS-CoV lacking the E gene (rSARS-Cov-E), produces significant neutralizing antibodies and virus-specific T cell responses<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref>
<sup>,</sup>
<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref>. More recently, a live attenuated SARS-CoV was generated through mutation of transcription regulatory networks (TRNs), where the attenuated virus effectively limits virulence reversal and protects mice against challenge<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref>. Another study reported that rMERS-CoV-&#x00394;E, a mutant of the MERS-CoV prepared using a new DNA cloning vector system, only replicates in a small number of cells, but can produce enough antigen to stimulate protective immunity in the host<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref>. Although vaccine candidates based on the live-attenuated coronaviruses have the potential to induce a highly effective immune response and protection, it may present biosafety problems associated with virulence recovery<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref>.</p></sec><sec id="sec3.2"><label>3.2</label><title>Nucleic acid-based vaccines</title><p id="p0080">Nucleic acid vaccines, including DNA and RNA vaccines, are based on plasmids or messenger RNA that encode vaccine antigens, and they are introduced into the host to produce immunological response to protect organisms against diseases<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>. The efficacy of DNA-based vaccines against SARS-CoV and MERS-CoV infections has been widely evaluated. In a phase I clinical trial, a SARS DNA vaccine produces cellular immune responses and neutralizing antibody in healthy adults<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref>. Additionally, a DNA vaccine encoding the MERS-CoV S protein induces strong CD8<sup>+</sup> and CD4<sup>+</sup> T cell immunity and antigen-specific neutralizing antibodies in mice, camels and nonhuman primates (NHPs), and protects vaccinated rhesus macaques from infection by MERS-CoV<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref>
<sup>,</sup>
<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref>. GLS-5300, a DNA vaccine expressing MERS-CoV S-protein antigen, is the first MERS-CoV vaccine to advance into human trials. The vaccine induced durable immune responses, as most participants maintained detectable S1 binding antibodies and had cellular immune responses at almost 1 year after the last vaccination<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref>. Nevertheless, CoV DNA vaccines based on full-length S protein may cause a Th2-related harmful immune response, leading to liver damage in vaccinated animals. One study comparing the immunogenicity of MERS-CoV DNA vaccines expressing S or S1 in mice showed that plasmids expressing the S1 (pS1) subunit triggered a balanced Th1/Th2 response, thereby avoiding the risk of immunopathological risk associated with Th2 response<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref>. Moreover, immunization of mice with pS1 vaccine induced significantly higher levels of IFN-<italic>&#x003b3;</italic> compared to pS vaccine<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref>.</p><p id="p0085">Messenger RNA (mRNA) vaccines carry transcripts encoding antigens, and use the host cell translational machinery to produce the antigens, which then stimulates an immune response<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref>. Because of high yields of <italic>in vitro</italic> transcription reactions, mRNA has the potential for rapid, inexpensive and scalable manufacturing, which greatly shortens the development time and can respond quickly to epidemics. Compared to DNA vaccines, mRNA vaccines do not need to pass an additional membrane barrier (nuclear membrane), so it does not have safety concerns about integration into the host genome<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref>. Due to the above advantages, mRNA vaccines are becoming a powerful tool against coronavirus infection.</p><p id="p0090">However, their application has been restricted by the instability and inefficient <italic>in vivo</italic> delivery of nucleic acid (DNA or mRNA)<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref>
<sup>,</sup>
<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref>. To provide protection from degradation and facilitate their entry into targeted cells, efficient delivery systems for nucleic acid vaccines, particularly the nanocarriers, have been explored extensively.</p></sec><sec id="sec3.3"><label>3.3</label><title>Viral-vector vaccines</title><p id="p0095">Viral vectors have a molecular mechanism that assists the target gene to enter cells and infect them, which is an important vector platform for CoV candidate vaccines. Viral vector-based vaccines encoding S protein of MERS-CoV and SARS-CoV have been widely studied. To date, adenovirus (Ad), modified vaccinia ankara (MVA), attenuated parainfluenza virus (BHPIV3) and rabies virus (RV) have been used as vaccine vector<xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref>, <xref rid="bib71" ref-type="bibr">71</xref>, <xref rid="bib72" ref-type="bibr">72</xref>, <xref rid="bib73" ref-type="bibr">73</xref>. A previous report has indicated SARS-CoV S-specific neutralizing antibodies and mucosal responses are elicited in African green monkeys immunized with BHPIV3/SARS-S vector vaccines, protecting African green monkeys against SARS-CoV infection<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref>. Another study reported that a single inoculation with the RV-based vaccine expressing SARS-CoV S protein can induce a strong SARS-CoV-neutralizing antibody response<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref>. In addition, MERS-CoV S-specific neutralizing antibodies and antigen specific T cell response, are induced in mice after immunizing them with human adenovirus or MVA-based MERS-CoV S-expressing vaccines<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref>
<sup>,</sup>
<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref>. Furthermore, compared with MERS-CoV S-encoding Ad5 vaccines, MERS-CoV S1-encoding Ad5 vaccines might induce higher levels of neutralizing antibodies<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref>. In a recent study, rAd5 constructs expressing CD40-targeted S1 fusion protein (rAd5-S1/F/CD40L) exhibited full protection against lethal MERS-CoV challenge, and prevented severe perivascular hemorrhage within the lungs as compared to non CD40-targeted vaccine (rAd5-S1)<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref>. Currently, MERS-CoV S protein expressed by chimpanzee adenovirus (ChAdOx1) or modified vaccinia Ankara (MVA) vectors are at phase I clinical trial<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref>
<sup>,</sup>
<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref>. Indeed, viral vectors expressing S protein can induce viral neutralizing antibodies <italic>in vivo</italic>, providing an effective platform for the development of SARS-CoV-2 vaccine. However, some viral-vectors, such as certain serotypes of adenoviruses, may fail to induce effective immune responses owing to the high prevalence of virus-neutralizing antibodies in the human population resulting in elimination of viral vectors<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref>. Thus, caution should be taken when developing CoV vaccines using viral vectors.</p></sec><sec id="sec3.4"><label>3.4</label><title>Virus-like particle (VLP) vaccines</title><p id="p0100">Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of native viruses but devoid of infectious genetic materials. VLP is a potential candidate for the development of safe and effective CoV vaccines, which can efficiently stimulate innate and adaptive immune response functions. Bacterial, insect, yeast and mammalian cells expression systems have been widely used in the production of VLPs. One study indicated a chimeric VLPs that coexpression of SARS-CoV S protein and E, M and N proteins of mouse hepatitis virus resulted in the efficient production of neutralizing antibodies, thus inhibiting SARS-CoV replication in the lung<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref>. The other chimeric VLPs, expressing SARS-CoV S protein and influenza M1 protein, can induce neutralizing antibodies and protect mice against deadly challenges<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref>. Similar as SARS-CoV VLP vaccines that induce high titers of neutralizing antibodies against CoV infection, MERS-CoV VLP vaccines also elicit antigen specific cellular immune response against infections of MERS-CoV<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref>. The VLP vaccine is a potential tool to provide protection against novel pandemic pathogens. However, VLPs as a preventive vaccine still have many problems to be considered. For example, viral mutations might allow the virus to evade antibody-mediated neutralization.</p></sec><sec id="sec3.5"><label>3.5</label><title>Subunit vaccines</title><p id="p0105">Subunit vaccines are composed of highly purified antigens which require only a part of the pathogen to generate a protective immune response. Subunit vaccines are characterized by high security, controllable performance and easy production on a large scale, thereby gradually becoming the focus of more and more researchers. Compared to the full-length S protein, RBD contains several critical neutralizing epitopes and lacks non-neutralizing epitopes that may cause harmful pathological responses. Therefore, RBD-based subunit vaccines not only can induce effective neutralizing antibodies, but also avoid adverse immune responses. From the safety and effectiveness perspectives, the RBD-based CoV vaccines are more attractive candidates in the development of CoV vaccines.</p><p id="p0110">Since the SARS and MERS outbreaks, subunit vaccines based on SARS-CoV and MERS-CoV RBD have been extensively studied and tested, showing sufficient effectiveness and strong protection against CoV infection in various animal models<xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref>, <xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib84" ref-type="bibr">84</xref>, <xref rid="bib85" ref-type="bibr">85</xref>. For example, RBD-Fc (RBD fused with human IgG1 Fc) elicits long-term humoral immune response, and produces neutralizing antibodies that protects the vaccinated mice from the SARS-CoV challenge without causing immunopathological damage<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref>. Also, a newly designed RBD without the Fc tag induces robust humoral and T cell responses, particularly neutralizing antibodies in immunized mice, protecting mice against SARS-CoV infection<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref>. It has been demonstrated that S377-588-Fc, which is a fusion protein of RBD fragment S377-588 (spike residues 377&#x02012;588) and human IgG1 Fc, induces the higher-titer IgG antibodies and neutralizing antibodies among all RBD fragments in mice<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref>. A study has also shown that i.n. vaccination of MERS-CoV RBD-Fc induces humoral IgG antibody response comparable to those induced by s.c. vaccination, including neutralizing antibodies, but more robust systemic cellular immune responses and higher local mucosal immune responses in mouse lungs<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref>. In the rhesus macaque, a recombinant receptor-binding domain (rRBD) protein vaccine can also induce sustained and robust immunological responses<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref>. These studies suggest that RBD-based CoV vaccines have potential for preventing respiratory infections caused by CoV, further enhancing beneficial strategies for emerging coronavirus infection. However, it is worth noting that highly purified proteins are generally low immunogenicity and often require the addition of vaccine adjuvants.</p><p id="p0115">To summarize, an effective vaccine against coronavirus infection often needs to induce the body to produce strong humoral immune response and cellular immune response. The current advancements and vaccine strategies in the development of in the development of SARS-CoV vaccines and MERS-CoV vaccines are listed in <xref rid="tbl2" ref-type="table">Table 2</xref>
<xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>
<sup>,</sup>
<xref rid="bib55" ref-type="bibr">55</xref>, <xref rid="bib56" ref-type="bibr">56</xref>, <xref rid="bib57" ref-type="bibr">57</xref>, <xref rid="bib58" ref-type="bibr">58</xref>
<sup>,</sup>
<xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib63" ref-type="bibr">63</xref>
<sup>,</sup>
<xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref>, <xref rid="bib71" ref-type="bibr">71</xref>, <xref rid="bib72" ref-type="bibr">72</xref>, <xref rid="bib73" ref-type="bibr">73</xref>, <xref rid="bib74" ref-type="bibr">74</xref>
<sup>,</sup>
<xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref>, <xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref>
<sup>,</sup>
<xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref>, <xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref>
<sup>.</sup> Apart from inactivated and live-attenuated virus vaccines, nucleic acid-, viral vector- and VLPs-based vaccines, particularly subunit vaccines containing the RBD of CoV S protein, are critically important.<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Vaccine strategies of SARS-CoV and MERS-CoV.</p></caption><alt-text id="alttext0045">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Vaccine strategy</th><th rowspan="2">Process of production</th><th colspan="2">Result and reference<hr/></th></tr><tr><th>SARS-CoV</th><th>MERS-CoV</th></tr></thead><tbody><tr><td>Inactivated virus vaccines</td><td>Virus particles are inactivated by physical or chemical methods</td><td>1. Induces S-specific antibody responses and neutralizing antibodies in mice (1:7393) and rabbit (1:2060), neutralizes pseudotyped SARS-CoV<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref>.<break/>2. Induces neutralizing antibodies in mice in ferret (1: 128-256), neutralizes SARS-CoV; reduces the virus titer in the respiratory tract, and provides protective immunity<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref>.</td><td>Induces S-specific antibody responses and neutralizing antibodies in mice (&#x0003e;1:10<sup>3</sup>); neutralizes pseudotyped MERS-CoV<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref>.</td></tr><tr><td>Live-attenuated virus vaccines</td><td>Genomes are mutated by mutagenesis or targeted deletions</td><td>1. Induces SARS-CoV-specific antibody responses and neutralizing antibodies in 6-week-old mice (1:10<sup>2</sup>&#x02012;10<sup>3</sup>) and 12-month-old mice (1:10<sup>2</sup>&#x02012;10<sup>3</sup>), neutralizes SARS-CoV Urbani strain; elicts T-cell responses and protectes all mice (6-week-old/12-month-old) against challenge with virulent virus<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref>.<break/>2. Induces SARS-CoV-specific antibody responses and T cell responses in BALB/c and hACE2 Tg mice; protectes 60%&#x02012;70% of mice against challenge with virulent virus<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref>.<break/>3. The TRN-rewired SARS-CoV is attenuated and protect against lethal SARS-CoV challenge<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref>.</td><td>rMERS-CoV-E generated by reverse genetics system is a replication-competent, propagation-defective virus<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref>.</td></tr><tr><td>Nucleic acid-based vaccines</td><td>Genetically engineered DNA/mRNA encode antigenic compounds</td><td>Induces S-specific antibody responses and neutralizing antibodies in 80% subjects, neutralizes pseudotyped SARS-CoV; elicts T-cell responses in all subjects<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref>.</td><td>1. Induces S-specific antibody responses and neutralizing antibodies in mice (&#x0003e;1:10<sup>2</sup>), camels (1:600&#x02012;700) and rhesus macaques (&#x0003e;1:10<sup>2</sup>), neutralizes MERS-CoV strain (EMC/2012); elicts T-cell responses in rhesus macaques and protects 100% of rhesus macaques from viral challenge<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref>.<break/>2. Induces S1-specific antibody responses and neutralizing antibodies in 77% subjects, neutralizes MERS-CoV strain (EMC/2012); elicts T-cell responses in 64% subjects<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref>.</td></tr><tr><td>Viral-vector vaccines</td><td>Inserting foreign gene units into the viral genome by homologous recombination</td><td>1. Induces neutralizing antibodies in African green monkeys (&#x02248;1:16) immunized with BHPIV3-SARS-S vector vaccine, neutralizes SARS-CoV; protectes all african green monkeys against challenge with virulent virus<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref>.<break/>2. Induces neutralizing antibodies in mice (1:160) immunized with RV-SARS-S vector vaccine; neutralizes SARS-CoV<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref>.</td><td>1. Induces neutralizing antibodies in mice (1: 64&#x02012;128) immunized with MVA-MERS-S vector vaccine, neutralizes MERS-CoV; elict T-cell responses and reduces virus titers in the lung<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref>.<break/>2. Induces S-specific antibody responses and neutralizing antibodies in mice (&#x0003e;1:10<sup>3</sup>) immunized with Ad5/Ad41-MERS-S vector vaccine, neutralizes pseudotyped MERS-CoV; elicts T-cell responses<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref>.<break/>3. Induces S-specific IgG subtype antibody (IgG1 and IgG2a) and neutralizing antibodies in mice (&#x0003e;1:10<sup>3</sup>) immunized with Ad5-MERS-S1 vector vaccine, neutralizes MERS-CoV strain (EMC/2012)<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref>.<break/>4. Induces S1-specific IgG subtype antibody (IgG1 and IgG2a) and neutralizing antibodies in mice (1:10<sup>2</sup>&#x02012;10<sup>3</sup>/1:10<sup>3</sup>&#x02012;10<sup>4</sup>) immunized with rAd5-S1/F/CD40 vaccine, neutralizes pseudotyped and live MERS-CoV<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref>.</td></tr><tr><td>Virus-like particle (VLPs) vaccines</td><td>Genes clone viral structural proteins into expression system</td><td>1. Induce neutralizing antibodies in mice (1: 200&#x000b1; 97.7), neutralizes SARS-CoV; reduces virus titers in the lung<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref>.<break/>2. Induce neutralizing antibodies in mice (1:875&#x02012;1525), neutralizes SARS-CoV Urbani strain; reduces virus titers in the lung and protects all mice against challenge with virulent virus<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref>.</td><td>Induced RBD-specific antibody responses and neutralizing antibodies in mice (1: 320), neutralizes pseudotyped MERS-CoV; elict T-cell responses<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref>.</td></tr><tr><td>Subunit vaccines</td><td>Antigenic components including immunogenic pathogen fragment without nucleic acid</td><td>1. Induce S-specific antibody responses and neutralizing antibodies in mice (1:4.0&#x000d7;10<sup>3</sup>&#x000b1;3.5&#x000d7;10<sup>2</sup>), neutralizes SARS-CoV BJ01 strain; protects 80% of the mice from the virus challenge<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref>.<break/>2. Induces RBD-specific antibody responses and neutralizing antibodies in mouse (1:5.8&#x000d7;10<sup>4</sup>&#x000b1;4.9&#x000d7;10<sup>3</sup>/1:1.0&#x000d7;10<sup>3</sup>&#x000b1;2.4&#x000d7;10<sup>2</sup>), neutralizes pseudotyped and live SARS-CoV; elict T-cell responses and protects all mice against challenge with virulent virus<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref>.</td><td>Induced RBD-specific antibody responses and neutralizing antibodies in in rhesus monkey (1:1600), neutralizes pseudotyped MERS-CoV; elicts T-cell responses and reduces virus titers<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref>.</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="sec4"><label>4</label><title>Adjuvant systems for improving the immunogenicity of coronavirus subunit vaccines</title><p id="p0120">Highly purified proteins in subunit vaccines are usually not inherently immunogenic, as they generally do not directly stimulate the innate immune system. However, the development of effective CoV vaccines requires the activation of powerful humoral and cellular immunity to induce protective immunity and virus clearance in the body. Therefore, adjuvants are needed to be incorporated in subunit vaccines to enhance the immunogenicity of these weaker antigens and evoke the required antigen-specific immune response phenotype, thus improving the overall potency of poorly immunogenic subunit vaccines. The following review will discuss adjuvants commonly used in subunit vaccines against coronavirus infection.</p><sec id="sec4.1"><label>4.1</label><title>Aluminum-based adjuvants</title><p id="p0125">Aluminum (Alum) adjuvant is the longest and most frequently used adjuvant in licensed vaccines, with an extensive safety record. Alum is a Th2-type adjuvant that induces strong humoral immune response, including the production of neutralizing antibodies<xref rid="bib86" ref-type="bibr"><sup>86</sup></xref>. Therefore, Alum is incorporated into a range of vaccines against viral infection where neutralizing antibodies to viral antigens are required for protection, including human papillomavirus, rabies and hepatitis B<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref>.</p><p id="p0130">Aluminum adjuvant has been widely used in the development of CoV vaccine due to a variety of advantages noted above. Several studies have indicated that RBD-based subunit vaccines in the presence of alum induce powerful serum-specific and neutralizing antibodies, providing a degree of protection against viral challenges<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref>
<sup>,</sup>
<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref>. It is noteworthy to mention that eliciting powerful cellular and humoral immunity is critical for a potential CoV vaccine. Virus-specific T cells can secrete IFN-<italic>&#x003b3;</italic> and promote virus clearance. Meanwhile, effector T cells can further differentiate into memory T cells, which is expected to respond quickly and effectively to subsequent CoV infection<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref>
<sup>,</sup>
<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref>. Although alum successfully induces antibody-mediated protective immunity, its ability to induce cellular immune responses is limited. One approach to overcome the limitations of alum is to use it in combination with other adjuvants to enhance cellular immune responses.</p></sec><sec id="sec4.2"><label>4.2</label><title>Emulsions</title><p id="p0135">Another approach that has an extensive history of use as CoV vaccine adjuvants are emulsions. Freund&#x02019;s adjuvant is a water-in-oil emulsion, divided into complete Freund&#x02019;s adjuvant (CFA) and incomplete Freund&#x02019;s adjuvant (IFA). As a powerful agonist for Th1 cells, CFA can induce Th1 cytokines and enhance cellular and humoral immune responses. While IFA generally induce Th2 cytokines<xref rid="bib91" ref-type="bibr">91</xref>, <xref rid="bib92" ref-type="bibr">92</xref>, <xref rid="bib93" ref-type="bibr">93</xref>. Mice immunized with SARS-CoV rRBD antigen together with Freund&#x02019;s adjuvant induce not just high titer of neutralizing antibodies, but relatively high levels of CTL and Th responses<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref>. Freund&#x02019;s adjuvant induces a more balanced Th1 and Th2 immune response, providing more comprehensive protection against coronavirus infection. Freund&#x02019;s adjuvant is not approved for use in human vaccines due to its toxicity<xref rid="bib95" ref-type="bibr"><sup>95</sup></xref>. Despite this, Montanide ISA-51, also known as incomplete Freund&#x02019;s adjuvant (IFA), has been approved for human use in 2012<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref>
<sup>,</sup>
<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref>. Similar as classic Freund&#x02019;s water emulsion, the addition of Montanide ISA-51 in RBD-based vaccines can produce strong antigen-specific neutralizing antibodies response against CoV infection<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref>
<sup>,</sup>
<xref rid="bib98" ref-type="bibr"><sup>98</sup></xref>.</p><p id="p0140">The toxicity of Freund&#x02019;s adjuvant mainly comes from the non-degradable oil in the ingredients. To avoid the toxicity problem of Freund&#x02019;s adjuvant, oil-in-water emulsions prepared from biocompatible oils such as squalene (<italic>e</italic>.<italic>g</italic>., SAS and MF59) were developed<xref rid="bib99" ref-type="bibr">99</xref>, <xref rid="bib100" ref-type="bibr">100</xref>, <xref rid="bib101" ref-type="bibr">101</xref>. The Sigma adjuvant system (SAS) is a stable oil-in-water emulsion containing monophosphoryl lipid A, which has been used in animal experiments. One study indicated that the SARS-CoV rRBD protein with SAS protect mouse against lethal SARS-CoV challenge, where the protection correlated well with the high titer of neutralizing antibodies<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref>. In addition, MERS-CoV S1 protein together with SAS was identified to elicit robust serum neutralizing activity against several MERS-CoV strains in immunized mice<xref rid="bib103" ref-type="bibr"><sup>103</sup></xref>.</p><p id="p0145">MF59, another squalene-based oil-in-water emulsion, has been licensed in Europe for adjuvanted influenza vaccines. It is revealed that MERS-CoV RBD in trimeric form with MF59 elicits highly efficacious Th2-based IgG1 and Th1-based IgG2 antibody responses, as well as neutralizing antibodies against pseudotyped and live MERS-CoV, protecting 83% of hDPP4-Tg mice from lethal MERS-CoV infection (<xref rid="fig4" ref-type="fig">Fig. 4</xref>
)<xref rid="bib99" ref-type="bibr">99</xref>, <xref rid="bib100" ref-type="bibr">100</xref>, <xref rid="bib101" ref-type="bibr">101</xref>. Similarly, the activation of IgG subtype antibody response and production of neutralizing antibodies following immunization with RBD-Fc and MF59, resulting in the fully protection against MERS-CoV infection<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref>. Additionally, MF59 induces stronger and broader IgG subtype antibody response than several other commercial adjuvants, including Freund&#x02019;s adjuvant, aluminum, Monophosphoryl lipid A and Montanide ISA51<xref rid="bib99" ref-type="bibr">99</xref>, <xref rid="bib100" ref-type="bibr">100</xref>, <xref rid="bib101" ref-type="bibr">101</xref>. Based on the security and effectiveness of MF59, it becomes a promising candidate adjuvant for the development of coronavirus subunit vaccine.<fig id="fig4"><label>Figure 4</label><caption><p>MERS-CoV RBD in trimeric form with MF59 protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. (A) Schematic structure of MERS-CoV S1 subunit and construction of RBD-Fd. A His6 tag was added at the C-terminus of RBD-Fd (B) MERS-CoV S1-specific IgG antibody titers. (C) and (D) MERS-CoV S1-specific IgG1 and IgG2a antibody titers. (E) and (F) neutralizing antibody levels against infections of pseudotyped and live MERS-CoV of EMC2012 strain. (G) Survival rate of MERS-CoV infected mice after vaccination. Fd: foldon. The figure was adapted with permission from ref. 104. Copyright &#x000a9; 2017 Elsevier.</p></caption><alt-text id="alttext0030">Figure 4</alt-text><graphic xlink:href="gr4_lrg"/></fig></p></sec><sec id="sec4.3"><label>4.3</label><title>Toll-Like receptors (TLRs) agonist</title><p id="p0150">The innate immune system recognizes pathogen-associated molecular patterns (PAMPS) mainly through pattern recognition receptors (PRRs). As one of the best characterized PRRs, Toll-like receptors (TLRs), which are widely distributed in antigen presenting cells and play an important role in triggering innate immunity and priming the adaptive immune response<xref rid="bib107" ref-type="bibr"><sup>107</sup></xref>. Therefore, several TLR agonists have been investigating as virus-specific vaccine adjuvants to induce strong and sustained immune responses<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref>
<sup>,</sup>
<xref rid="bib109" ref-type="bibr"><sup>109</sup></xref>.</p><p id="p0155">The Toll-like receptor (TLR) families have been characterized as key players in RNA virus detection and antiviral immunity. Polyinosinic acid&#x02012;polycytidylic acid (PolyI:C) is a synthetic double-stranded RNA (dsRNA) analogue that acts as a TLR3 receptor agonist, inducing the production of type I IFN and inflammatory cytokines through a TRIF-dependent pathway<xref rid="bib110" ref-type="bibr"><sup>110</sup></xref>. Previous reports have indicated mice deficient in the TLR3 signaling way are extremely susceptible to SARS-CoV infection, showing increased lung pathology and higher viral titers<xref rid="bib111" ref-type="bibr"><sup>111</sup></xref>. Additionally, intranasal treatment with PolyI:C induces both innate and T cell immune responses against viral infections, protecting aged animals from infection by IAV or SARS-CoV, as well as providing more rapid virus clearance<xref rid="bib112" ref-type="bibr"><sup>112</sup></xref>. Furthermore, MERS-CoV S protein together with poly I:C effectively trigger CD8 T-Cells response to accelerate MERS-CoV clearance without immunopathological effects<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref>. These results suggest that PolyI:C, a potent type I IFN inducer, should be evaluated as a promising adjuvant in CoV subunit vaccines.</p><p id="p0160">TLR4 mainly recognizes lipopolysaccharide (LPS) derived from the cell wall of gram-negative bacteria. Unlike other TLRs, TLR4 agonists mediate the production of inflammatory cytokines and type I IFN <italic>via</italic> MyD88 as well as TRIF signaling pathway<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref>. It has been demonstrated that pretreatment with TLR4 ligands provides protective immunity against infections by SARS-CoV<xref rid="bib112" ref-type="bibr"><sup>112</sup></xref>. Monophosphoryl lipid A (MPLA)&#x02014;a TLR4 agonist&#x02014;is an attenuated version of lipopolysaccharide (LPS). MPLA has proven its safety and effectiveness in licensed vaccines, including human papillomavirus and hepatitis B vaccines<xref rid="bib115" ref-type="bibr"><sup>115</sup></xref>
<sup>,</sup>
<xref rid="bib116" ref-type="bibr"><sup>116</sup></xref>. Previous work has shown that inclusion of MPLA as an adjuvant in influenza vaccine promotes mucosal and systemic (Th1-skewed) immune responses after pulmonary vaccination<xref rid="bib117" ref-type="bibr"><sup>117</sup></xref>. In addition, SARS-CoV S protein with adjuvanated TLR3 and TLR4 agonists successfully induce high expression of antigen-specific IgG and neutralizing antibodies without eosinophilic infiltrations and elicit Th1/17 cytokine responses in the lungs after the SARS-CoV challenge infection in the mouse model<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref>. The above results indicated that TLR4 agonist, as a powerful Th1-type adjuvant, can effectively improve the immunogenicity of the CoV subunit vaccines and reduce the Th2-related eosinophilic pathological response.</p><p id="p0165">TLR9 recognizes unmethylated cytosine-phosphate-guanine (CpG) motifs that are commonly found in bacterial and viral DNA, and then mediates the antiviral response of type I IFN <italic>via</italic> the TLR9-MyD88 pathway<xref rid="bib119" ref-type="bibr"><sup>119</sup></xref>. CpG-containing oligodeoxynucleotides (CpG ODN) sequence 1018, as an adjuvant for immunization against hepatitis B virus (HBV), has been proven to significantly increase neutralizing antibody titers in clinical trials<xref rid="bib120" ref-type="bibr"><sup>120</sup></xref>. Recently it has been approved for adults in the United States<xref rid="bib121" ref-type="bibr"><sup>121</sup></xref>. A novel CpG ODN (BW001) has been shown to effectively activate B and NK cells and stimulate the body to secrete high level of IFN-a and IFN-<italic>&#x003b3;</italic>, thereby producing strong anti-SARS-CoV activity<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref>. Furthermore, CpG have been identified to be superior to other TLR agonists (TLR3 agonists: PolyI:C; TLR7/8 agonists: R848) in the secretion of inflammatory cytokines and activation of SARS-CoV S peptide specific CD8<sup>+</sup> T cell response<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref>. Due to the strong ability of CpG to induce cellular immunity, it is often used in combination with alum to supplement the defects of alum in inducing cellular immunity. For instance, mice immunized with SARS-CoV S protein amino acids 318&#x02013;510 (S318&#x02013;510) together with alum and CpG ODN show higher humoral and cellular immune responses than those immunized with S318&#x02013;510 antigen and alum alone (<xref rid="fig5" ref-type="fig">Fig. 5</xref>
)<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref>
<sup>,</sup>
<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref>. The above findings suggest that CpG can be used as a potent adjuvant for coronavirus vaccines.<fig id="fig5"><label>Figure 5</label><caption><p>Mice immunized with SARS-CoV spike protein amino acids 318&#x02013;510 (S318&#x02013;510) with alum plus CpG elicited strong antibody and cellular immune responses. (A) SARS-CoV-specific IgG antibody titers. (B) SARS-CoV-specific IgG1 and IgG2a antibody titers. (C) Neutralizing antibody levels against infections of SARS-CoV of Tor-2 strain. The figure was adapted with permission from ref. 124. Copyright &#x000a9; 2007 Elsevier.</p></caption><alt-text id="alttext0035">Figure 5</alt-text><graphic xlink:href="gr5_lrg"/></fig></p></sec><sec id="sec4.4"><label>4.4</label><title>Stimulator of interferon genes (STING) agonists</title><p id="p0170">STING (stimulator of interferon genes), a central component in the innate immune response, plays an important role in defense against viral and intracellular bacterial infections. STING is a transmembrane protein localized to the endoplasmic reticulum. Following stimulation by cytosolic cyclic dinucleotides (CDNs), STING undergoes a conformational change, resulting in a downstream signaling cascade involving the activation of NF-<italic>&#x003ba;</italic>B signaling pathway and the production of type I interferon<xref rid="bib125" ref-type="bibr"><sup>125</sup></xref>
<sup>,</sup>
<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref>. STING agonists are potent adjuvants capable of eliciting robust humoral and CD8<sup>+</sup> T cell immune responses in mice by simulating the early phase of viral infection without concomitant excess inflammation<xref rid="bib127" ref-type="bibr"><sup>127</sup></xref>. Meanwhile, recombinant MERS-CoV RBD antigens with cyclic diguanylate monophosphate (cdGMP), a canonical STING agonist, have shown to effectively elicit neutralization antibody and antigen&#x02010;specific T cell responses<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref>
<sup>.</sup>
</p><p id="p0175">To summarize, the application of vaccine adjuvant requires a thorough understanding of the effect of adjuvants on immune response and mechanisms of action. The application of adjuvants in subunit vaccines are listed in <xref rid="tbl3" ref-type="table">Table 3</xref>
<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref>
<sup>,</sup>
<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref>
<sup>,</sup>
<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref>
<sup>,</sup>
<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref>
<sup>,</sup>
<xref rid="bib91" ref-type="bibr">91</xref>, <xref rid="bib92" ref-type="bibr">92</xref>, <xref rid="bib93" ref-type="bibr">93</xref>, <xref rid="bib94" ref-type="bibr">94</xref>
<sup>,</sup>
<xref rid="bib98" ref-type="bibr">98</xref>, <xref rid="bib99" ref-type="bibr">99</xref>, <xref rid="bib100" ref-type="bibr">100</xref>, <xref rid="bib101" ref-type="bibr">101</xref>, <xref rid="bib102" ref-type="bibr">102</xref>, <xref rid="bib103" ref-type="bibr">103</xref>, <xref rid="bib104" ref-type="bibr">104</xref>, <xref rid="bib105" ref-type="bibr">105</xref>, <xref rid="bib106" ref-type="bibr">106</xref>
<sup>,</sup>
<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref>
<sup>,</sup>
<xref rid="bib109" ref-type="bibr"><sup>109</sup></xref>
<sup>,</sup>
<xref rid="bib112" ref-type="bibr"><sup>112</sup></xref>
<sup>,</sup>
<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref>
<sup>,</sup>
<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref>
<sup>,</sup>
<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref>
<sup>,</sup>
<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref>
<sup>,</sup>
<xref rid="bib125" ref-type="bibr"><sup>125</sup></xref>
<sup>,</sup>
<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref>
<sup>,</sup>
<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref>. In addition to safety considerations, the design of adjuvants must also pay attention to the ability to selectively induce and regulate the types of immune responses in the body, so as to effectively promote the humoral and cellular immunity to combat coronavirus infection. It is also noteworthy to mention that an existing well-established adjuvant could be combined with new immunostimulants (<italic>e</italic>.<italic>g</italic>., TLRs agonist) to improve the breadth and intensity of the immune responses, which has become a potential strategy for exploring efficient adjuvant systems.<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Application of adjuvants in subunit vaccines.</p></caption><alt-text id="alttext0050">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Adjuvant</th><th>Composition</th><th>Mechanism</th><th>Antibody responses and neutralizing antibody</th><th>Cellular immune response</th></tr></thead><tbody><tr><td>Alum</td><td>Aluminum hydroxide/Aluminum phosphate</td><td>1. Promotes a strong Th2-biased response(humoral immune response)<break/>2. Depot effect<break/>3. Inflammatory response<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref></td><td>1. Induces MERS-CoV RBD-specific antibody responses and neutralizing antibodies (1:1600) in rhesus macaque; neutralizes pseudotyped MERS-CoV<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref>.<break/>2. Induces MERS-CoV RBD-specific antibody responses<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref>.</td><td>No-report</td></tr><tr><td colspan="5">Emulsions</td></tr><tr><td>Freund&#x02019;s adjuvant</td><td>IFA: an water-in-oil emulsion formed by mixing mineral oil with an emulsifier<break/>CFA: killed bacteria <italic>M. tuberculosis</italic> added to IFA</td><td rowspan="2">1. Continuous release of immunogenic substances in oil droplets<break/>2. Inflammatory response<break/>3. Stimulates the production of antibodies<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref><sup>,</sup><xref rid="bib92" ref-type="bibr"><sup>92</sup></xref><sup>,</sup><xref rid="bib93" ref-type="bibr"><sup>93</sup></xref><break/></td><td>Induces SARS-CoV RBD-specific antibody responses and neutralizing antibodies (&#x0003e;1:10<sup>4</sup>/1:10<sup>2</sup>-10<sup>3</sup>) in mice; neutralizes pseudotyped and live SARS-CoV<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref>.</td><td>Elicits SARS-CoV RBD-specific T cell responses in mice<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref>.</td></tr><tr><td>Montanide ISA51</td><td>IFA</td><td>1. Induces MERS-CoV RBD-specific antibody responses and neutralizing antibodies (&#x0003e;1:10<sup>3</sup>) in mice; neutralizes live MERS-CoV<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref>.<break/>2. Induces neutralizing antibodies(1:240&#x000b1;139) in mouse; neutralizes live MERS-CoV<xref rid="bib98" ref-type="bibr"><sup>98</sup></xref>.</td><td>No-report</td></tr><tr><td>Sigma adjuvant system (SAS)</td><td>Oil-in-water emulsion containing monophosphoryl lipid A</td><td rowspan="2">1. Enhances antigen uptake at the injection site<break/>2. Induces the production of cytokines and chemokines<break/>3. Recruits immune cells to the injection site<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref><sup>,</sup><xref rid="bib100" ref-type="bibr"><sup>100</sup></xref><sup>,</sup><xref rid="bib101" ref-type="bibr"><sup>101</sup></xref></td><td>1. Induces SARS-CoV RBD-specific antibody responses and neutralizing antibodies (1:6.9&#x000d7;10<sup>5</sup>/1:1.6&#x000d7;10<sup>3</sup>) in mice; neutralizes pseudotyped and live SARS-CoV<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref>.<break/>2. Induces neutralizing antibodies (1:10<sup>2</sup>&#x02012;10<sup>3</sup>) in mice; neutralizes eight MERS-CoV strain<xref rid="bib103" ref-type="bibr"><sup>103</sup></xref>.</td><td>No-report</td></tr><tr><td>MF59</td><td>Squalene-based oil-in-water emulsion</td><td>1. Induces MERS-CoV RBD-specific IgG subtype antibody (IgG1 and IgG2a) and neutralizing antibodies (1:100&#x02012;673) in mice; neutralizes live MERS-CoV<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref>.<break/>2. Induces MERS-CoV S1-specific IgG subtype antibody (IgG1 and IgG2a) and neutralizing antibodies (1:10<sup>3</sup>&#x02012;10<sup>4</sup>) in mice; neutralizes pseudotyped and live MERS-CoV<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref>.</td><td>No significant increase in t-cell response<xref rid="bib106" ref-type="bibr"><sup>106</sup></xref>.</td></tr><tr><td colspan="5">Toll-Like Receptors (TLRs) agonists</td></tr><tr><td>TLR3 agonist</td><td>Double-stranded RNA (dsRNA) analogue</td><td rowspan="3">1. The recognition of receptor stimulates innate immune responses such as antiviral and inflammatory responses<break/>2. Induce adaptive immune responses<break/>3. Activate immune cells and induce the production of Cytokines<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref><sup>,</sup><xref rid="bib109" ref-type="bibr"><sup>109</sup></xref></td><td>No-Report</td><td>1. Induces the expression of IFN-associated molecule, elicits T cell responses<xref rid="bib112" ref-type="bibr"><sup>112</sup></xref>.<break/>2. Induces the production of type-I IFN, elicits T cell responses<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref>.</td></tr><tr><td>TLR4 agonist</td><td>LPS/MPLA</td><td>Induces SARS-CoV S-specific antibody and virus-specific antibody (&#x0003e;1:10<sup>4</sup>)<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref>.</td><td>Induces the production of Th1 cytokines, elicits T cell responses<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref>.</td></tr><tr><td>TLR9 agonist</td><td>CpG DNA</td><td>No-report</td><td>1. Induces the production of IFN-a and IFN-&#x003b3;, enhance NK cell cytotoxicity<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref>.<break/>2. Induces cytotoxicity T cells response and memory T cells response<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref>.</td></tr><tr><td colspan="5">Stimulator of interferon genes (STING) agonists</td></tr><tr><td>STING agonist</td><td>cdGMP</td><td>1. Activates the production of host defense molecules and cytokines<break/>2. Induces adaptive immune responses<xref rid="bib125" ref-type="bibr"><sup>125</sup></xref><sup>,</sup><xref rid="bib126" ref-type="bibr"><sup>126</sup></xref></td><td>Induces MERS-CoV RBD-specific IgG subtype antibody (IgG1 and IgG2a) and neutralizing antibodies (1:40&#x02012;320) in mice; neutralizes live MERS-CoV<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref><sub>.</sub></td><td>Induces the production of IFN-<italic>&#x003b3;</italic> and memory T cells response<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref>.</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="sec5"><label>5</label><title>Conclusions and perspectives</title><p id="p0180">SARS-CoV-2 has spread rapidly since its outbreak and has now posed a risk to countries worldwide, making it urgent to develop a safe and effective vaccine against the infection. This review introduces the structure and functions of coronavirus S protein and summarizes the advancements and potential strategies of SARS-CoV and MERS-CoV vaccines based on CoV S protein. The CoV S protein-based vaccines are further classified into different types, including viral vector, nucleic acid (DNA and RNA), VLP and protein-based vaccines. Subunit vaccines have become the focus of current research due to their numerous advantages, but it often requires appropriate adjuvants to enhance their immunogenicity. In the USA, aluminum, MF59, and CpG are adjuvants included in licensed vaccines. These three adjuvants have shown induction of serum neutralizing antibodies and protection against infection in mice challenged with an infectious virus, which might be used for CoV subunit vaccine administration<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref>
<sup>,</sup>
<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref>
<sup>,</sup>
<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref>
<sup>,</sup>
<xref rid="bib106" ref-type="bibr"><sup>106</sup></xref>
<sup>,</sup>
<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref>
<sup>,</sup>
<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref>. However, alum alone cannot induce a potent Th1 response unless combined with another adjuvant, such as CpG. This adjuvant combination will improve the effectiveness of the CoV subunit vaccines<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref>. Similarly, in order to effectively activate the complex and orderly natural immune system and produce the expected acquired immune response, it is sometimes necessary to use an adjuvant combination<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref>. Here, we believe that adjuvant formulations that induce a balanced Th1 and Th2 immune response can more effectively improve the immunogenicity of the antigen<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref>
<sup>,</sup>
<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref>
<sup>,</sup>
<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref>, becoming a new trend in the development of coronavirus adjuvants. Ideally, an effective CoV vaccine is required to induce both robust humoral and cell-mediated immunities. Even though many promising vaccine candidates have been reported, there are still no commercial vaccines available against SARS-CoV and MERS-CoV. The comprehensive lessons and experiences brought by the outbreak of SARS and MERS provide valuable insights and progress on how to respond to COVID-19.</p><p id="p0185">With the spread of COVID-19, scientific institutions and pharmaceutical companies around the world are racing against time to develop SARS-CoV-2 vaccine. According to WHO, there are at least 100 research projects on SARS-CoV-2 vaccines in the world<xref rid="bib129" ref-type="bibr"><sup>129</sup></xref>. In addition to traditional inactivated virus and live-attenuated virus vaccines, the developments of most SARS-CoV-2 vaccines are also based on some new technological routes, such as mRNA vaccines, subunit vaccines, viral vector vaccines, and DNA vaccines. Up to now, eight candidate vaccines have entered clinical trials, including three inactivated vaccines from Wuhan Institute of Biological Products<xref rid="bib130" ref-type="bibr"><sup>130</sup></xref>, Beijing Institute of Biological Products<xref rid="bib131" ref-type="bibr"><sup>131</sup></xref> and Sinovac<xref rid="bib132" ref-type="bibr"><sup>132</sup></xref>, two adenovirus vector vaccines (Ad5-nCoV from CanSino Biologicals<xref rid="bib133" ref-type="bibr"><sup>133</sup></xref> and COV001 from Inovio<xref rid="bib134" ref-type="bibr"><sup>134</sup></xref>), two mRNA vaccines (mRNA-1273 from Moderna<xref rid="bib135" ref-type="bibr"><sup>135</sup></xref> and BNT162 from BioNTech<xref rid="bib136" ref-type="bibr"><sup>136</sup></xref>) and one DNA vaccine (INO-4800 from Inovio<xref rid="bib137" ref-type="bibr"><sup>137</sup></xref>). Although some progress has been made in the development of SARS-CoV-2 vaccines, it is important to realize that vaccine development is a rigorous scientific exploration process. Due to many challenges of verifying the effectiveness of vaccines, it is still very likely that no SARS-CoV-2 vaccine will be available in the market for human in near future. Therefore, SARS-CoV-2 vaccine development still requires the unremitting efforts of researchers in the world.</p></sec><sec id="sec6"><title>Author contributions</title><p id="p0190">Chunting He and Ming Qin collected and reorganized the literature material. Chunting He wrote the manuscript. Xun Sun revised the manuscript. All of the authors have read and approved the final manuscript.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0195">There are no conflicts of interest to declare.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N Engl J Med</source><volume>382</volume><year>2020</year><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="bib2"><label>2</label><mixed-citation publication-type="other" id="sref2">World Helath Organization. Coronavirus disease (COVID-2019) situation reports; c2020 [cited 2020 May 16th]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports" id="intref0010">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</ext-link>.</mixed-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>T.</given-names></name><name><surname>Khan</surname><given-names>M.</given-names></name><name><surname>Haroon</surname></name><name><surname>Musa</surname><given-names>T.H.</given-names></name><name><surname>Nasir</surname><given-names>S.</given-names></name><name><surname>Hui</surname><given-names>J.</given-names></name></person-group><article-title>COVID-19: zoonotic aspects</article-title><source>Travel Med Infect Dis</source><year>2020</year><fpage>101607</fpage><pub-id pub-id-type="pmid">32112857</pub-id></element-citation></ref><ref id="bib4"><label>4</label><mixed-citation publication-type="other" id="sref4">World Health Organization. Cumulative number of reported probable cases of severe acute respiratory syndrome (SARS); c2003-2004 [cited 2020 March 30]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/country/en/" id="intref0015">http://www.who.int/csr/sars/country/en/</ext-link>.</mixed-citation></ref><ref id="bib5"><label>5</label><mixed-citation publication-type="other" id="sref5">World Helath Organization. Middle East respiratory syndrome coronavirus (MERS-CoV); c2012-2019 [cited 2020 March 30]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/" id="intref0020">https://www.who.int/emergencies/mers-cov/en/</ext-link>.</mixed-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>He</surname><given-names>Y.Q.</given-names></name><name><surname>Liu</surname><given-names>X.L.</given-names></name><name><surname>Zhuang</surname><given-names>Z.X.</given-names></name><name><surname>Cheung</surname><given-names>C.L.</given-names></name></person-group><article-title>Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China</article-title><source>Science</source><volume>302</volume><year>2003</year><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">12958366</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Alagaili</surname><given-names>A.N.</given-names></name><name><surname>Briese</surname><given-names>T.</given-names></name><name><surname>Mishra</surname><given-names>N.</given-names></name><name><surname>Kapoor</surname><given-names>V.</given-names></name><name><surname>Sameroff</surname><given-names>S.C.</given-names></name><name><surname>Burbelo</surname><given-names>P.D.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia</article-title><source>mBio</source><volume>5</volume><year>2014</year><comment>e00884-14</comment></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.L.</given-names></name><name><surname>Wang</surname><given-names>X.G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P.C.</given-names></name><name><surname>Lau</surname><given-names>S.K.</given-names></name><name><surname>Lam</surname><given-names>C.S.</given-names></name><name><surname>Lau</surname><given-names>C.C.</given-names></name><name><surname>Tsang</surname><given-names>A.K.</given-names></name><name><surname>Lau</surname><given-names>J.H.</given-names></name></person-group><article-title>Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus</article-title><source>J Virol</source><volume>86</volume><year>2012</year><fpage>3995</fpage><lpage>4008</lpage><pub-id pub-id-type="pmid">22278237</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Muth</surname><given-names>D.</given-names></name><name><surname>Niemeyer</surname><given-names>D.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name></person-group><article-title>Hosts and sources of endemic human coronaviruses</article-title><source>Adv Virus Res</source><volume>100</volume><year>2018</year><fpage>163</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">29551135</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Lienau</surname><given-names>J.</given-names></name><name><surname>Witzenrath</surname><given-names>M.</given-names></name></person-group><article-title>Coronaviren als Ursache respiratorischer Infektionen [Coronaviruses as the cause of respiratory infections]</article-title><source>Internist (Berl)</source><volume>60</volume><year>2019</year><fpage>1136</fpage><lpage>1145</lpage><pub-id pub-id-type="pmid">31455974</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Tong</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Sutter</surname><given-names>K.</given-names></name></person-group><article-title>Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV</article-title><source>J Med Virol</source><volume>92</volume><year>2020</year><fpage>491</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">32056249</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Structure, function, and evolution of coronavirus spike proteins</article-title><source>Annu Rev Virol</source><volume>3</volume><year>2016</year><fpage>237</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">27578435</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>A.R.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title><source>Methods Mol Biol</source><volume>1282</volume><year>2015</year><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">25720466</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A.C.</given-names></name><name><surname>Park</surname><given-names>Y.J.</given-names></name><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Wall</surname><given-names>A.</given-names></name><name><surname>McGuire</surname><given-names>A.T.</given-names></name><name><surname>Veesler</surname><given-names>D.</given-names></name></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>281</fpage><lpage>292</lpage><comment>e6</comment><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>P.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Pan</surname><given-names>B.</given-names></name></person-group><article-title>Understanding of COVID-19 based on current evidence</article-title><source>J Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25722</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Mou</surname><given-names>H.</given-names></name><name><surname>Smits</surname><given-names>S.L.</given-names></name><name><surname>Dekkers</surname><given-names>D.H.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.A.</given-names></name><name><surname>Dijkman</surname><given-names>R.</given-names></name></person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title><source>Nature</source><volume>495</volume><year>2013</year><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">23486063</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Belouzard</surname><given-names>S.</given-names></name><name><surname>Millet</surname><given-names>J.K.</given-names></name><name><surname>Licitra</surname><given-names>B.N.</given-names></name><name><surname>Whittaker</surname><given-names>G.R.</given-names></name></person-group><article-title>Mechanisms of coronavirus cell entry mediated by the viral spike protein</article-title><source>Viruses</source><volume>4</volume><year>2012</year><fpage>1011</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">22816037</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Beniac</surname><given-names>D.R.</given-names></name><name><surname>deVarennes</surname><given-names>S.L.</given-names></name><name><surname>Andonov</surname><given-names>A.</given-names></name><name><surname>He</surname><given-names>R.</given-names></name><name><surname>Booth</surname><given-names>T.F.</given-names></name></person-group><article-title>Conformational reorganization of the SARS coronavirus spike following receptor binding: implications for membrane fusion</article-title><source>PLoS One</source><volume>2</volume><year>2007</year><comment>e1082</comment></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>MERS-CoV spike protein: targets for vaccines and therapeutics</article-title><source>Antiviral Res</source><volume>133</volume><year>2016</year><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">27468951</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name><name><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name><surname>Hsieh</surname><given-names>C.L.</given-names></name><name><surname>Abiona</surname><given-names>O.</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><year>2020</year><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Kuwahara</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name></person-group><article-title>Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates</article-title><source>ACS Infect Dis</source><volume>2</volume><year>2016</year><fpage>361</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">27627203</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>van den Brand</surname><given-names>J.M.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Volz</surname><given-names>A.</given-names></name><name><surname>Wohlsein</surname><given-names>P.</given-names></name><name><surname>Smits</surname><given-names>S.L.</given-names></name></person-group><article-title>An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels</article-title><source>Science</source><volume>351</volume><year>2016</year><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">26678878</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Alharbi</surname><given-names>N.K.</given-names></name><name><surname>Padron-Regalado</surname><given-names>E.</given-names></name><name><surname>Thompson</surname><given-names>C.P.</given-names></name><name><surname>Kupke</surname><given-names>A.</given-names></name><name><surname>Wells</surname><given-names>D.</given-names></name><name><surname>Sloan</surname><given-names>M.A.</given-names></name></person-group><article-title>ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice</article-title><source>Vaccine</source><volume>35</volume><year>2017</year><fpage>3780</fpage><lpage>3788</lpage><pub-id pub-id-type="pmid">28579232</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Okba</surname><given-names>N.M.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches</article-title><source>Curr Opin Virol</source><volume>23</volume><year>2017</year><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">28412285</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Weingartl</surname><given-names>H.</given-names></name><name><surname>Czub</surname><given-names>M.</given-names></name><name><surname>Czub</surname><given-names>S.</given-names></name><name><surname>Neufeld</surname><given-names>J.</given-names></name><name><surname>Marszal</surname><given-names>P.</given-names></name><name><surname>Gren</surname><given-names>J.</given-names></name></person-group><article-title>Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets</article-title><source>J Virol</source><volume>78</volume><year>2004</year><fpage>12672</fpage><lpage>12676</lpage><pub-id pub-id-type="pmid">15507655</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.F.</given-names></name><name><surname>Tseng</surname><given-names>S.P.</given-names></name><name><surname>Yen</surname><given-names>C.H.</given-names></name><name><surname>Yang</surname><given-names>J.Y.</given-names></name><name><surname>Tsao</surname><given-names>C.H.</given-names></name><name><surname>Shen</surname><given-names>C.W.</given-names></name></person-group><article-title>Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins</article-title><source>Biochem Biophys Res Commun</source><volume>451</volume><year>2014</year><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">25073113</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Okba</surname><given-names>N.M.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches</article-title><source>Curr Opin Virol</source><volume>23</volume><year>2017</year><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">28412285</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Garron</surname><given-names>T.</given-names></name></person-group><article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus</article-title><source>Cell Mol Immunol</source><volume>13</volume><year>2016</year><fpage>180</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">25640653</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name></person-group><article-title>Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><comment>e112602</comment></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Nyon</surname><given-names>M.P.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Tseng</surname><given-names>C.K.</given-names></name><name><surname>Seid</surname><given-names>C.A.</given-names></name><name><surname>Pollet</surname><given-names>J.</given-names></name><name><surname>Naceanceno</surname><given-names>K.S.</given-names></name></person-group><article-title>Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen</article-title><source>Vaccine</source><volume>36</volume><year>2018</year><fpage>1853</fpage><lpage>1862</lpage><pub-id pub-id-type="pmid">29496347</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus</article-title><source>DNA Cell Biol</source><volume>24</volume><year>2005</year><fpage>510</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">16101349</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Ulitzky</surname><given-names>L.</given-names></name><name><surname>Silberstein</surname><given-names>E.</given-names></name><name><surname>Taylor</surname><given-names>D.R.</given-names></name><name><surname>Viscidi</surname><given-names>R.</given-names></name></person-group><article-title>Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates</article-title><source>Viral Immunol</source><volume>26</volume><year>2013</year><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">23573979</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Keng</surname><given-names>C.T.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Lip</surname><given-names>K.M.</given-names></name><name><surname>Fielding</surname><given-names>B.C.</given-names></name><name><surname>Tan</surname><given-names>T.H.</given-names></name></person-group><article-title>Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents</article-title><source>J Virol</source><volume>79</volume><year>2005</year><fpage>3289</fpage><lpage>3296</lpage><pub-id pub-id-type="pmid">15731223</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Nie</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Lian</surname><given-names>G.</given-names></name></person-group><article-title>Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies</article-title><source>J Virol</source><volume>78</volume><year>2004</year><fpage>6938</fpage><lpage>6945</lpage><pub-id pub-id-type="pmid">15194770</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>L.T.</given-names></name><name><surname>Wang</surname><given-names>L.Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Z.Q.</given-names></name></person-group><article-title>Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients</article-title><source>Virology</source><volume>351</volume><year>2006</year><fpage>466</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">16690096</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>C.Y.</given-names></name><name><surname>Ong</surname><given-names>H.K.</given-names></name><name><surname>Yeap</surname><given-names>S.K.</given-names></name><name><surname>Ho</surname><given-names>K.L.</given-names></name><name><surname>Tan</surname><given-names>W.S.</given-names></name></person-group><article-title>Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus</article-title><source>Front Microbiol</source><volume>10</volume><year>2019</year><fpage>1781</fpage><pub-id pub-id-type="pmid">31428074</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Buchholz</surname><given-names>U.J.</given-names></name><name><surname>Bukreyev</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name></person-group><article-title>Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><year>2004</year><fpage>9804</fpage><lpage>9809</lpage><pub-id pub-id-type="pmid">15210961</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Yasui</surname><given-names>F.</given-names></name><name><surname>Kai</surname><given-names>C.</given-names></name><name><surname>Kitabatake</surname><given-names>M.</given-names></name><name><surname>Inoue</surname><given-names>S.</given-names></name><name><surname>Yoneda</surname><given-names>M.</given-names></name><name><surname>Yokochi</surname><given-names>S.</given-names></name></person-group><article-title>Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV</article-title><source>J Immunol</source><volume>181</volume><year>2008</year><fpage>6337</fpage><lpage>6348</lpage><pub-id pub-id-type="pmid">18941225</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>M.S.</given-names></name><name><surname>Chen</surname><given-names>W.J.</given-names></name><name><surname>Chen</surname><given-names>H.Y.</given-names></name><name><surname>Lin</surname><given-names>S.F.</given-names></name><name><surname>Wang</surname><given-names>M.C.</given-names></name><name><surname>Di</surname><given-names>J.</given-names></name></person-group><article-title>Neutralizing antibody response and SARS severity</article-title><source>Emerg Infect Dis</source><volume>11</volume><year>2005</year><fpage>1730</fpage><lpage>1737</lpage><pub-id pub-id-type="pmid">16318725</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>J.D.</given-names></name><name><surname>Hay</surname><given-names>K.</given-names></name><name><surname>Rini</surname><given-names>J.M.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Plummer</surname><given-names>F.A.</given-names></name></person-group><article-title>Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology</article-title><source>mAbs</source><volume>2</volume><year>2010</year><fpage>53</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">20168090</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>C.M.</given-names></name><name><surname>Venkataraman</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>Y.V.</given-names></name><name><surname>Glenn</surname><given-names>G.M.</given-names></name><name><surname>Smith</surname><given-names>G.E.</given-names></name><name><surname>Flyer</surname><given-names>D.C.</given-names></name></person-group><article-title>MERS-CoV spike nanoparticles protect mice from MERS-CoV infection</article-title><source>Vaccine</source><volume>35</volume><year>2017</year><fpage>1586</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">28237499</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Van Rooijen</surname><given-names>N.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice</article-title><source>PLoS Pathog</source><volume>5</volume><year>2009</year><comment>e1000636</comment></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Alshukairi</surname><given-names>A.N.</given-names></name><name><surname>Baharoon</surname><given-names>S.A.</given-names></name><name><surname>Ahmed</surname><given-names>W.A.</given-names></name><name><surname>Bokhari</surname><given-names>A.A.</given-names></name><name><surname>Nehdi</surname><given-names>A.M.</given-names></name></person-group><article-title>Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses</article-title><source>Sci Immunol</source><volume>2</volume><year>2017</year><comment>eaan5393</comment></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Mangalam</surname><given-names>A.K.</given-names></name><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Fett</surname><given-names>C.</given-names></name><name><surname>Meyerholz</surname><given-names>D.K.</given-names></name></person-group><article-title>Airway memory CD4<sup>+</sup> T cells mediate protective immunity against emerging respiratory coronaviruses</article-title><source>Immunity</source><volume>44</volume><year>2016</year><fpage>1379</fpage><lpage>1391</lpage><pub-id pub-id-type="pmid">27287409</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>F.</given-names></name><name><surname>Quan</surname><given-names>Y.</given-names></name><name><surname>Xin</surname><given-names>Z.T.</given-names></name><name><surname>Wrammert</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>M.J.</given-names></name><name><surname>Lv</surname><given-names>H.</given-names></name></person-group><article-title>Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study</article-title><source>J Immunol</source><volume>186</volume><year>2011</year><fpage>7264</fpage><lpage>7268</lpage><pub-id pub-id-type="pmid">21576510</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Siddiqui</surname><given-names>P.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry</article-title><source>Biochem Biophys Res Commun</source><volume>325</volume><year>2004</year><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">15530413</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>See</surname><given-names>R.H.</given-names></name><name><surname>Petric</surname><given-names>M.</given-names></name><name><surname>Lawrence</surname><given-names>D.J.</given-names></name><name><surname>Mok</surname><given-names>C.P.Y.</given-names></name><name><surname>Rowe</surname><given-names>T.</given-names></name><name><surname>Zitzow</surname><given-names>L.A.</given-names></name></person-group><article-title>Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines</article-title><source>J Gen Virol</source><volume>89</volume><year>2008</year><fpage>2136</fpage><lpage>2146</lpage><pub-id pub-id-type="pmid">18753223</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus</article-title><source>Emerg Microbes Infect</source><volume>7</volume><year>2018</year><fpage>60</fpage><pub-id pub-id-type="pmid">29618723</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>C.T.</given-names></name><name><surname>Sbrana</surname><given-names>E.</given-names></name><name><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name><name><surname>Newman</surname><given-names>P.C.</given-names></name><name><surname>Garron</surname><given-names>T.</given-names></name><name><surname>Atmar</surname><given-names>R.L.</given-names></name></person-group><article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><comment>e35421</comment></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>A.S.</given-names></name><name><surname>Tao</surname><given-names>X.</given-names></name><name><surname>Algaissi</surname><given-names>A.</given-names></name><name><surname>Garron</surname><given-names>T.</given-names></name><name><surname>Narayanan</surname><given-names>K.</given-names></name><name><surname>Peng</surname><given-names>B.H.</given-names></name></person-group><article-title>Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</article-title><source>Hum Vaccin Immunother</source><volume>12</volume><year>2016</year><fpage>2351</fpage><lpage>2356</lpage><pub-id pub-id-type="pmid">27269431</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Spruth</surname><given-names>M.</given-names></name><name><surname>Kistner</surname><given-names>O.</given-names></name><name><surname>Savidis-Dacho</surname><given-names>H.</given-names></name><name><surname>Hitter</surname><given-names>E.</given-names></name><name><surname>Crowe</surname><given-names>B.</given-names></name><name><surname>Gerencer</surname><given-names>M.</given-names></name></person-group><article-title>A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses</article-title><source>Vaccine</source><volume>24</volume><year>2006</year><fpage>652</fpage><lpage>661</lpage><pub-id pub-id-type="pmid">16214268</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Legge</surname><given-names>K.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice</article-title><source>J Clin Invest</source><volume>121</volume><year>2011</year><fpage>4921</fpage><lpage>4930</lpage><pub-id pub-id-type="pmid">22105170</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Frieman</surname><given-names>M.</given-names></name><name><surname>Yount</surname><given-names>B.</given-names></name><name><surname>Agnihothram</surname><given-names>S.</given-names></name><name><surname>Page</surname><given-names>C.</given-names></name><name><surname>Donaldson</surname><given-names>E.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name></person-group><article-title>Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease</article-title><source>J Virol</source><volume>86</volume><year>2012</year><fpage>884</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">22072787</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Fett</surname><given-names>C.</given-names></name><name><surname>DeDiego</surname><given-names>M.L.</given-names></name><name><surname>Regla-Nava</surname><given-names>J.A.</given-names></name><name><surname>Enjuanes</surname><given-names>L.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein</article-title><source>J Virol</source><volume>87</volume><year>2013</year><fpage>6551</fpage><lpage>6559</lpage><pub-id pub-id-type="pmid">23576515</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Netland</surname><given-names>J.</given-names></name><name><surname>DeDiego</surname><given-names>M.L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Fett</surname><given-names>C.</given-names></name><name><surname>&#x000c1;lvarez</surname><given-names>E.</given-names></name><name><surname>Nieto-Torres</surname><given-names>J.L.</given-names></name></person-group><article-title>Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease</article-title><source>Virology</source><volume>399</volume><year>2010</year><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">20110095</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Deming</surname><given-names>D.J.</given-names></name><name><surname>Deming</surname><given-names>M.E.</given-names></name><name><surname>Yount</surname><given-names>B.L.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform</article-title><source>Commun Biol</source><volume>1</volume><year>2018</year><fpage>179</fpage><pub-id pub-id-type="pmid">30393776</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Almaz&#x000e1;n</surname><given-names>F.</given-names></name><name><surname>DeDiego</surname><given-names>M.L.</given-names></name><name><surname>Sola</surname><given-names>I.</given-names></name><name><surname>Zu&#x000f1;iga</surname><given-names>S.</given-names></name><name><surname>Nieto-Torres</surname><given-names>J.L.</given-names></name><name><surname>Marquez-Jurado</surname><given-names>S.</given-names></name></person-group><article-title>Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate</article-title><source>mBio</source><volume>4</volume><year>2013</year><comment>e00650-13</comment></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>S.</given-names></name><name><surname>Jasny</surname><given-names>E.</given-names></name><name><surname>Schmidt</surname><given-names>K.E.</given-names></name><name><surname>Petsch</surname><given-names>B.</given-names></name></person-group><article-title>New vaccine technologies to combat outbreak situations</article-title><source>Front Immunol</source><volume>9</volume><year>2018</year><fpage>1963</fpage><pub-id pub-id-type="pmid">30283434</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>J.E.</given-names></name><name><surname>Louder</surname><given-names>M.K.</given-names></name><name><surname>Holman</surname><given-names>L.A.</given-names></name><name><surname>Gordon</surname><given-names>I.J.</given-names></name><name><surname>Enama</surname><given-names>M.E.</given-names></name><name><surname>Larkin</surname><given-names>B.D.</given-names></name></person-group><article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial</article-title><source>Vaccine</source><volume>26</volume><year>2008</year><fpage>6338</fpage><lpage>6343</lpage><pub-id pub-id-type="pmid">18824060</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Muthumani</surname><given-names>K.</given-names></name><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>Reuschel</surname><given-names>E.L.</given-names></name><name><surname>Tingey</surname><given-names>C.</given-names></name><name><surname>Flingai</surname><given-names>S.</given-names></name><name><surname>Villarreal</surname><given-names>D.O.</given-names></name></person-group><article-title>A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates</article-title><source>Sci Transl Med</source><volume>7</volume><year>2015</year><comment>301ra132</comment></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Cockrell</surname><given-names>A.S.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>An effective DNA vaccine platform for Middle East respiratory syndrome coronavirus</article-title><source>Ann Transl Med</source><volume>4</volume><year>2016</year><fpage>499</fpage><pub-id pub-id-type="pmid">28149861</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Modjarrad</surname><given-names>K.</given-names></name><name><surname>Roberts</surname><given-names>C.C.</given-names></name><name><surname>Mills</surname><given-names>K.T.</given-names></name><name><surname>Castellano</surname><given-names>A.R.</given-names></name><name><surname>Paolino</surname><given-names>K.</given-names></name><name><surname>Muthumani</surname><given-names>K.</given-names></name></person-group><article-title>Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial</article-title><source>Lancet Infect Dis</source><volume>19</volume><year>2019</year><fpage>1013</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">31351922</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Al-Amri</surname><given-names>S.S.</given-names></name><name><surname>Abbas</surname><given-names>A.T.</given-names></name><name><surname>Siddiq</surname><given-names>L.A.</given-names></name><name><surname>Alghamdi</surname><given-names>A.</given-names></name><name><surname>Sanki</surname><given-names>M.A.</given-names></name><name><surname>Al-Muhanna</surname><given-names>M.K.</given-names></name></person-group><article-title>Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein</article-title><source>Sci Rep</source><volume>7</volume><year>2017</year><fpage>44875</fpage><pub-id pub-id-type="pmid">28332568</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Recent advances in mRNA vaccine delivery</article-title><source>Nano Research</source><volume>11</volume><year>2018</year><fpage>5338</fpage><lpage>5354</lpage></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Pardi</surname><given-names>N.</given-names></name><name><surname>Hogan</surname><given-names>M.J.</given-names></name><name><surname>Porter</surname><given-names>F.W.</given-names></name><name><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccines&#x02014;a new era in vaccinology</article-title><source>Nat Rev Drug Discov</source><volume>17</volume><year>2018</year><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">29326426</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Geall</surname><given-names>A.J.</given-names></name><name><surname>Mandl</surname><given-names>C.W.</given-names></name><name><surname>Ulmer</surname><given-names>J.B.</given-names></name></person-group><article-title>RNA: the new revolution in nucleic acid vaccines</article-title><source>Semin Immunol</source><volume>25</volume><year>2013</year><fpage>152</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">23735226</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Hobernik</surname><given-names>D.</given-names></name><name><surname>Bros</surname><given-names>M.</given-names></name></person-group><article-title>DNA vaccines-how far from clinical use?</article-title><source>Int J Mol Sci</source><volume>19</volume><year>2018</year><fpage>3605</fpage></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Bukreyev</surname><given-names>A.</given-names></name><name><surname>Lamirande</surname><given-names>E.W.</given-names></name><name><surname>Buchholz</surname><given-names>U.J.</given-names></name><name><surname>Vogel</surname><given-names>L.N.</given-names></name><name><surname>Elkins</surname><given-names>W.R.</given-names></name><name><surname>St Claire</surname><given-names>M.</given-names></name></person-group><article-title>Mucosal immunisation of African green monkeys (<italic>Cercopithecus aethiops</italic>) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS</article-title><source>Lancet</source><volume>363</volume><year>2004</year><fpage>2122</fpage><lpage>2127</lpage><pub-id pub-id-type="pmid">15220033</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Faber</surname><given-names>M.</given-names></name><name><surname>Lamirande</surname><given-names>E.W.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name><name><surname>Rice</surname><given-names>A.B.</given-names></name><name><surname>Koprowski</surname><given-names>H.</given-names></name><name><surname>Dietzschold</surname><given-names>B.</given-names></name></person-group><article-title>A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies</article-title><source>J Gen Virol</source><volume>86</volume><year>2005</year><fpage>1435</fpage><lpage>1440</lpage><pub-id pub-id-type="pmid">15831955</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Volz</surname><given-names>A.</given-names></name><name><surname>Kupke</surname><given-names>A.</given-names></name><name><surname>Song</surname><given-names>F.</given-names></name><name><surname>Jany</surname><given-names>S.</given-names></name><name><surname>Fux</surname><given-names>R.</given-names></name><name><surname>Shams-Eldin</surname><given-names>H.</given-names></name></person-group><article-title>Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East Respiratory Syndrome coronavirus spike glycoprotein</article-title><source>J Virol</source><volume>89</volume><year>2015</year><fpage>8651</fpage><lpage>8656</lpage><pub-id pub-id-type="pmid">26018172</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zou</surname><given-names>X.</given-names></name></person-group><article-title>Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus</article-title><source>Immunology</source><volume>145</volume><year>2015</year><fpage>476</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">25762305</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Okada</surname><given-names>K.</given-names></name><name><surname>Kenniston</surname><given-names>T.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>AlHajri</surname><given-names>M.M.</given-names></name><name><surname>Farag</surname><given-names>E.A.</given-names></name></person-group><article-title>Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>5975</fpage><lpage>5982</lpage><pub-id pub-id-type="pmid">25192975</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Hashem</surname><given-names>A.M.</given-names></name><name><surname>Algaissi</surname><given-names>A.</given-names></name><name><surname>Agrawal</surname><given-names>A.S.</given-names></name><name><surname>Al-Amri</surname><given-names>S.S.</given-names></name><name><surname>Alhabbab</surname><given-names>R.Y.</given-names></name><name><surname>Sohrab</surname><given-names>S.S.</given-names></name></person-group><article-title>A highly immunogenic, protective, and safe Adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model</article-title><source>J Infect Dis</source><volume>220</volume><year>2019</year><fpage>1558</fpage><lpage>1567</lpage><pub-id pub-id-type="pmid">30911758</pub-id></element-citation></ref><ref id="bib75"><label>75</label><mixed-citation publication-type="other" id="sref75">National Institutes of Health [NIH], 2018. Safety and immunogenicity of a candidate MERS-CoV vaccine (MERS001). Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT03399578" id="intref0025">https://clinicaltrials.gov/ct2/show/study/NCT03399578</ext-link>.</mixed-citation></ref><ref id="bib76"><label>76</label><mixed-citation publication-type="other" id="sref76">National Institutes of Health [NIH], 2018. Safety, tolerability and immunogenicity of vaccine candidate MVA-MERS-S. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03615911#outcomemeasures" id="intref0030">https://clinicaltrials.gov/ct2/show/NCT03615911#outcomemeasures</ext-link>.</mixed-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Lasaro</surname><given-names>M.O.</given-names></name><name><surname>Ertl</surname><given-names>H.C.</given-names></name></person-group><article-title>New insights on adenovirus as vaccine vectors</article-title><source>Mol Ther</source><volume>17</volume><year>2009</year><fpage>1333</fpage><lpage>1339</lpage><pub-id pub-id-type="pmid">19513019</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Lokugamage</surname><given-names>K.G.</given-names></name><name><surname>Yoshikawa-Iwata</surname><given-names>N.</given-names></name><name><surname>Ito</surname><given-names>N.</given-names></name><name><surname>Watts</surname><given-names>D.M.</given-names></name><name><surname>Wyde</surname><given-names>P.R.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name></person-group><article-title>Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV</article-title><source>Vaccine</source><volume>26</volume><year>2008</year><fpage>797</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">18191004</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.V.</given-names></name><name><surname>Massare</surname><given-names>M.J.</given-names></name><name><surname>Barnard</surname><given-names>D.L.</given-names></name><name><surname>Kort</surname><given-names>T.</given-names></name><name><surname>Nathan</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV</article-title><source>Vaccine</source><volume>29</volume><year>2011</year><fpage>6606</fpage><lpage>6613</lpage><pub-id pub-id-type="pmid">21762752</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Gai</surname><given-names>W.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name></person-group><article-title>Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice</article-title><source>Antiviral Res</source><volume>140</volume><year>2017</year><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">28040513</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model</article-title><source>Vaccine</source><volume>25</volume><year>2007</year><fpage>2832</fpage><lpage>2838</lpage><pub-id pub-id-type="pmid">17092615</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Chan</surname><given-names>C.C.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity</article-title><source>Viral Immunol</source><volume>23</volume><year>2010</year><fpage>211</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">20374001</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Tao</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Tseng</surname><given-names>C.K.</given-names></name></person-group><article-title>Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments&#x02014;the importance of immunofocusing in subunit vaccine design</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>6170</fpage><lpage>6176</lpage><pub-id pub-id-type="pmid">25240756</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Tao</surname><given-names>X.</given-names></name><name><surname>Tseng</surname><given-names>C.T.</given-names></name></person-group><article-title>Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>2100</fpage><lpage>2108</lpage><pub-id pub-id-type="pmid">24560617</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>Recombinant receptor binding domain protein induces partial protective immunity in <italic>Rhesus macaques</italic> against Middle East respiratory syndrome coronavirus challenge</article-title><source>EBioMedicine</source><volume>2</volume><year>2015</year><fpage>1438</fpage><lpage>1446</lpage><pub-id pub-id-type="pmid">26629538</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>He</surname><given-names>P.</given-names></name><name><surname>Zou</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name></person-group><article-title>Advances in aluminum hydroxide-based adjuvant research and its mechanism</article-title><source>Hum Vaccin Immunother</source><volume>11</volume><year>2015</year><fpage>477</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">25692535</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Baylor</surname><given-names>N.W.</given-names></name><name><surname>Egan</surname><given-names>W.</given-names></name><name><surname>Richman</surname><given-names>P.</given-names></name></person-group><article-title>Aluminum salts in vaccines&#x02014;US perspective</article-title><source>Vaccine</source><volume>20</volume><year>2002</year><fpage>S18</fpage><lpage>S23</lpage><pub-id pub-id-type="pmid">12184360</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y.S.</given-names></name><name><surname>Son</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Kwon</surname><given-names>S.B.</given-names></name><name><surname>Kim</surname><given-names>M.H.</given-names></name><name><surname>Kim</surname><given-names>P.</given-names></name></person-group><article-title>Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles</article-title><source>Front Immunol</source><volume>9</volume><year>2018</year><fpage>1093</fpage><pub-id pub-id-type="pmid">29868035</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Mubarak</surname><given-names>A.</given-names></name><name><surname>Alturaiki</surname><given-names>W.</given-names></name><name><surname>Hemida</surname><given-names>M.G.</given-names></name></person-group><article-title>Middle East Respiratory Syndrome Coronavirus (MERS-CoV): infection, immunological response, and vaccine development</article-title><source>J Immunol Res</source><volume>2019</volume><year>2019</year><fpage>6491738</fpage><pub-id pub-id-type="pmid">31089478</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Takamura</surname><given-names>S.</given-names></name></person-group><article-title>Persistence in temporary lung niches: a survival strategy of lung resident memory CD8<sup>+</sup> T cells</article-title><source>Viral Immunol</source><volume>30</volume><year>2017</year><fpage>438</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">28418771</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>F.C.</given-names></name><name><surname>Savary</surname><given-names>J.R.</given-names></name><name><surname>Diveley</surname><given-names>J.P.</given-names></name><name><surname>Chang</surname><given-names>J.C.</given-names></name></person-group><article-title>Adjuvant activity of incomplete Freund&#x02019;s adjuvant</article-title><source>Adv Drug Deliv Rev</source><volume>32</volume><year>1998</year><fpage>173</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">10837643</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Aucouturier</surname><given-names>J.</given-names></name><name><surname>Dupuis</surname><given-names>L.</given-names></name><name><surname>Ganne</surname><given-names>V.</given-names></name></person-group><article-title>Adjuvants designed for veterinary and human vaccines</article-title><source>Vaccine</source><volume>19</volume><year>2001</year><fpage>2666</fpage><lpage>2672</lpage><pub-id pub-id-type="pmid">11257407</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Stills</surname><given-names>H.F.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Adjuvants and antibody production: dispelling the myths associated with Freund&#x02019;s complete and other adjuvants</article-title><source>ILAR J</source><volume>46</volume><year>2005</year><fpage>280</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">15953835</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name></person-group><article-title>Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells</article-title><source>Biochem Biophys Res Commun</source><volume>384</volume><year>2009</year><fpage>486</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">19422787</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Stuewart-Tull</surname><given-names>D.E.</given-names></name><name><surname>Shimono</surname><given-names>T.</given-names></name><name><surname>Kotani</surname><given-names>S.</given-names></name><name><surname>Knights</surname><given-names>B.A.</given-names></name></person-group><article-title>Immunosuppressive effect in mycobacterial adjuvant emulsions of mineral oils containing low molecular weight hydrocarbons</article-title><source>Int Arch Allergy Appl Immunol</source><volume>52</volume><year>1976</year><fpage>118</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">797664</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Aucouturier</surname><given-names>J.</given-names></name><name><surname>Dupuis</surname><given-names>L.</given-names></name><name><surname>Deville</surname><given-names>S.</given-names></name><name><surname>Ascarateil</surname><given-names>S.</given-names></name><name><surname>Ganne</surname><given-names>V.</given-names></name></person-group><article-title>Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines</article-title><source>Expert Rev Vaccines</source><volume>1</volume><year>2002</year><fpage>111</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">12908518</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Sesardic</surname><given-names>D.</given-names></name><name><surname>Dobbelaer</surname><given-names>R.</given-names></name></person-group><article-title>European union regulatory developments for new vaccine adjuvants and delivery systems</article-title><source>Vaccine</source><volume>22</volume><year>2004</year><fpage>2452</fpage><lpage>2456</lpage><pub-id pub-id-type="pmid">15193409</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Kou</surname><given-names>Z.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Poon</surname><given-names>V.K.</given-names></name></person-group><article-title>Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development</article-title><source>J Virol</source><volume>87</volume><year>2013</year><fpage>9939</fpage><lpage>9942</lpage><pub-id pub-id-type="pmid">23824801</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name><surname>Sastry</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Joyce</surname><given-names>M.G.</given-names></name><name><surname>Kong</surname><given-names>W.P.</given-names></name><name><surname>Chuang</surname><given-names>G.Y.</given-names></name></person-group><article-title>Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus</article-title><source>PLoS One</source><volume>12</volume><year>2017</year><comment>e0186854</comment></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name><surname>Gavin</surname><given-names>A.L.</given-names></name><name><surname>Hoebe</surname><given-names>K.</given-names></name><name><surname>Duong</surname><given-names>B.</given-names></name><name><surname>Ota</surname><given-names>T.</given-names></name><name><surname>Martin</surname><given-names>C.</given-names></name></person-group><article-title>Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling</article-title><source>Science</source><volume>314</volume><year>2006</year><fpage>1936</fpage><lpage>1938</lpage><pub-id pub-id-type="pmid">17185603</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name><surname>O'Hagan</surname><given-names>D.T.</given-names></name><name><surname>Ott</surname><given-names>G.S.</given-names></name><name><surname>De Gregorio</surname><given-names>E.</given-names></name><name><surname>Seubert</surname><given-names>A.</given-names></name></person-group><article-title>The mechanism of action of MF59&#x02014;an innately attractive adjuvant formulation</article-title><source>Vaccine</source><volume>30</volume><year>2012</year><fpage>4341</fpage><lpage>4348</lpage><pub-id pub-id-type="pmid">22682289</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Chan</surname><given-names>C.C.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and <italic>E. coli</italic> cells elicits potent neutralizing antibody and protective immunity</article-title><source>Virology</source><volume>393</volume><year>2009</year><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">19683779</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Joyce</surname><given-names>M.G.</given-names></name><name><surname>Modjarrad</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Leung</surname><given-names>K.</given-names></name></person-group><article-title>Evaluation of candidate vaccine approaches for MERS-CoV</article-title><source>Nat Commun</source><volume>6</volume><year>2015</year><fpage>7712</fpage><pub-id pub-id-type="pmid">26218507</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Tao</surname><given-names>X.</given-names></name></person-group><article-title>A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection</article-title><source>Virology</source><volume>499</volume><year>2016</year><fpage>375</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">27750111</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Tai</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Tseng</surname><given-names>C.K.</given-names></name></person-group><article-title>Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection</article-title><source>Hum Vaccin Immunother</source><volume>13</volume><year>2017</year><fpage>1615</fpage><lpage>1624</lpage><pub-id pub-id-type="pmid">28277821</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Garron</surname><given-names>T.</given-names></name></person-group><article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus</article-title><source>Cell Mol Immunol</source><volume>13</volume><year>2016</year><fpage>180</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">25640653</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Toll-like receptors and their crosstalk with other innate receptors in infection and immunity</article-title><source>Immunity</source><volume>34</volume><year>2011</year><fpage>637</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">21616434</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name><surname>Lester</surname><given-names>S.N.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name></person-group><article-title>Toll-like receptors in antiviral innate immunity</article-title><source>J Mol Biol</source><volume>426</volume><year>2014</year><fpage>1246</fpage><lpage>1264</lpage><pub-id pub-id-type="pmid">24316048</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name><surname>Baum</surname><given-names>A.</given-names></name><name><surname>Garc&#x000ed;a-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>Induction of type I interferon by RNA viruses: cellular receptors and their substrates</article-title><source>Amino Acids</source><volume>38</volume><year>2010</year><fpage>1283</fpage><lpage>1299</lpage><pub-id pub-id-type="pmid">19882216</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name><surname>Oshiumi</surname><given-names>H.</given-names></name><name><surname>Matsumoto</surname><given-names>M.</given-names></name><name><surname>Funami</surname><given-names>K.</given-names></name><name><surname>Akazawa</surname><given-names>T.</given-names></name><name><surname>Seya</surname><given-names>T.</given-names></name></person-group><article-title>TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction</article-title><source>Nat Immunol</source><volume>4</volume><year>2003</year><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">12539043</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name><surname>Totura</surname><given-names>A.L.</given-names></name><name><surname>Whitmore</surname><given-names>A.</given-names></name><name><surname>Agnihothram</surname><given-names>S.</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name><name><surname>Katze</surname><given-names>M.G.</given-names></name><name><surname>Heise</surname><given-names>M.T.</given-names></name></person-group><article-title>Toll-like receptor 3 signaling <italic>via</italic> TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus Infection</article-title><source>mBio</source><volume>6</volume><year>2015</year><comment>e00638-15</comment></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Fleming</surname><given-names>E.</given-names></name><name><surname>Lane</surname><given-names>T.E.</given-names></name><name><surname>McCray</surname><given-names>P.B.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Intranasal treatment with poly(I&#x000b7;C) protects aged mice from lethal respiratory virus infections</article-title><source>J Virol</source><volume>86</volume><year>2012</year><fpage>11416</fpage><lpage>11424</lpage><pub-id pub-id-type="pmid">22915814</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name><surname>Agnihothram</surname><given-names>S.S.</given-names></name><name><surname>Fett</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Gale</surname><given-names>M.J.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Rapid generation of a mouse model for Middle East respiratory syndrome</article-title><source>Proc Natl Acad Sci U S A</source><volume>111</volume><year>2014</year><fpage>4970</fpage><lpage>4975</lpage><pub-id pub-id-type="pmid">24599590</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name><surname>Tanimura</surname><given-names>N.</given-names></name><name><surname>Saitoh</surname><given-names>S.</given-names></name><name><surname>Matsumoto</surname><given-names>F.</given-names></name><name><surname>Akashi-Takamura</surname><given-names>S.</given-names></name><name><surname>Miyake</surname><given-names>K.</given-names></name></person-group><article-title>Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling</article-title><source>Biochem Biophys Res Commun</source><volume>368</volume><year>2008</year><fpage>94</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">18222170</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name><surname>Didierlaurent</surname><given-names>A.M.</given-names></name><name><surname>Morel</surname><given-names>S.</given-names></name><name><surname>Lockman</surname><given-names>L.</given-names></name><name><surname>Giannini</surname><given-names>S.L.</given-names></name><name><surname>Bisteau</surname><given-names>M.</given-names></name><name><surname>Carlsen</surname><given-names>H.</given-names></name></person-group><article-title>AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity</article-title><source>J Immunol</source><volume>183</volume><year>2009</year><fpage>6186</fpage><lpage>6197</lpage><pub-id pub-id-type="pmid">19864596</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name><surname>Gar&#x000e7;on</surname><given-names>N.</given-names></name><name><surname>Chomez</surname><given-names>P.</given-names></name><name><surname>Van Mechelen</surname><given-names>M.</given-names></name></person-group><article-title>GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives</article-title><source>Expert Rev Vaccines</source><volume>6</volume><year>2007</year><fpage>723</fpage><lpage>739</lpage><pub-id pub-id-type="pmid">17931153</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>H.P.</given-names></name><name><surname>Murugappan</surname><given-names>S.</given-names></name><name><surname>ter Veer</surname><given-names>W.</given-names></name><name><surname>Meijerhof</surname><given-names>T.</given-names></name><name><surname>de Haan</surname><given-names>A.</given-names></name><name><surname>Frijlink</surname><given-names>H.W.</given-names></name></person-group><article-title>Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine</article-title><source>J Control Release</source><volume>174</volume><year>2014</year><fpage>51</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">24269505</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name><surname>Sekimukai</surname><given-names>H.</given-names></name><name><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name><name><surname>Fukushi</surname><given-names>S.</given-names></name><name><surname>Tani</surname><given-names>H.</given-names></name><name><surname>Kataoka</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name></person-group><article-title>Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs</article-title><source>Microbiol Immunol</source><volume>64</volume><year>2020</year><fpage>33</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">31692019</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name><surname>Latz</surname><given-names>E.</given-names></name><name><surname>Verma</surname><given-names>A.</given-names></name><name><surname>Visintin</surname><given-names>A.</given-names></name><name><surname>Gong</surname><given-names>M.</given-names></name><name><surname>Sirois</surname><given-names>C.M.</given-names></name><name><surname>Klein</surname><given-names>D.C.</given-names></name></person-group><article-title>Ligand-induced conformational changes allosterically activate Toll-like receptor 9</article-title><source>Nat Immunol</source><volume>8</volume><year>2007</year><fpage>772</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">17572678</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name><surname>Eng</surname><given-names>N.F.</given-names></name><name><surname>Bhardwaj</surname><given-names>N.</given-names></name><name><surname>Mulligan</surname><given-names>R.</given-names></name><name><surname>Diaz-Mitoma</surname><given-names>F.</given-names></name></person-group><article-title>The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV&#x02122; review</article-title><source>Hum Vaccin Immunother</source><volume>9</volume><year>2013</year><fpage>1661</fpage><lpage>1672</lpage><pub-id pub-id-type="pmid">23732907</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name><surname>Splawn</surname><given-names>L.M.</given-names></name><name><surname>Bailey</surname><given-names>C.A.</given-names></name><name><surname>Medina</surname><given-names>J.P.</given-names></name><name><surname>Cho</surname><given-names>J.C.</given-names></name></person-group><article-title>Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States</article-title><source>Drugs Today (Barc)</source><volume>54</volume><year>2018</year><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">30090877</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wan</surname><given-names>M.</given-names></name><name><surname>Dai</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name></person-group><article-title>Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide</article-title><source>Clin Immunol</source><volume>118</volume><year>2006</year><fpage>180</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">16298165</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name></person-group><article-title>The immune responses of HLA-A<sup>&#x02217;</sup>0201 restricted SARS-CoV S peptide-specific CD8&#x0207a; T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848</article-title><source>Vaccine</source><volume>29</volume><year>2011</year><fpage>6670</fpage><lpage>6678</lpage><pub-id pub-id-type="pmid">21745520</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name><surname>Zakhartchouk</surname><given-names>A.N.</given-names></name><name><surname>Sharon</surname><given-names>C.</given-names></name><name><surname>Satkunarajah</surname><given-names>M.</given-names></name><name><surname>Auperin</surname><given-names>T.</given-names></name><name><surname>Viswanathan</surname><given-names>S.</given-names></name><name><surname>Mutwiri</surname><given-names>G.</given-names></name></person-group><article-title>Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine</article-title><source>Vaccine</source><volume>25</volume><year>2007</year><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">16919855</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>J.</given-names></name><name><surname>Barber</surname><given-names>G.N.</given-names></name></person-group><article-title>STING signaling and host defense against microbial infection</article-title><source>Exp Mol Med</source><volume>51</volume><year>2019</year><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>T.</given-names></name><name><surname>Marutani</surname><given-names>Y.</given-names></name><name><surname>Shoji</surname><given-names>I.</given-names></name></person-group><article-title>Cytosolic DNA-sensing immune response and viral infection</article-title><source>Microbiol Immunol</source><volume>63</volume><year>2019</year><fpage>51</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">30677166</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Ji</given-names></name><name><surname>Li</surname><given-names>Peiyu</given-names></name><name><surname>Yu</surname><given-names>Yang</given-names></name><name><surname>Fu</surname><given-names>Yuhong</given-names></name><name><surname>Jiang</surname><given-names>Hongye</given-names></name><name><surname>Lu</surname><given-names>Min</given-names></name></person-group><article-title>Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity</article-title><source>Science</source><volume>367</volume><year>2020</year><fpage>869</fpage></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L.C.</given-names></name><name><surname>Huang</surname><given-names>C.Y.</given-names></name><name><surname>Yao</surname><given-names>B.Y.</given-names></name><name><surname>Lin</surname><given-names>J.C.</given-names></name><name><surname>Agrawal</surname><given-names>A.</given-names></name><name><surname>Algaissi</surname><given-names>A.</given-names></name></person-group><article-title>Viromimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against Middle East Respiratory Syndrome Coronavirus</article-title><source>Adv Funct Mater</source><volume>29</volume><year>2019</year><fpage>1807616</fpage><pub-id pub-id-type="pmid">32313544</pub-id></element-citation></ref><ref id="bib129"><label>129</label><mixed-citation publication-type="other" id="sref129">World Health Organization. Draft landscape of COVID-19 candidate vaccines; c2020 [cited 2020 May 16th]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines" id="intref0035">https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines</ext-link>.</mixed-citation></ref><ref id="bib130"><label>130</label><mixed-citation publication-type="other" id="sref130">Chinese Clinical Trial Registry. A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells); c2020 [cited 2020 May 16th]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/showprojen.aspx?proj=52227" id="intref0040">http://www.chictr.org.cn/showprojen.aspx?proj=52227</ext-link>.</mixed-citation></ref><ref id="bib131"><label>131</label><mixed-citation publication-type="other" id="sref131">Chinese Clinical Trial Registry. Evaluation of the safety and immunogenicity of inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) in healthy population aged 3 years and above: a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial; c2020 [cited 2020 May 16th]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/showproj.aspx?proj=53003" id="intref0045">http://www.chictr.org.cn/showproj.aspx?proj=53003</ext-link>.</mixed-citation></ref><ref id="bib132"><label>132</label><mixed-citation publication-type="other" id="sref132">National Institutes of Health. Safety and immunogenicity study of inactivated vaccine for prophylaxis of SARS CoV-2 infection (COVID-19); c2020 [cited 2020 May 16th]. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04352608" id="intref0050">https://clinicaltrials.gov/ct2/show/NCT04352608</ext-link>.</mixed-citation></ref><ref id="bib133"><label>133</label><mixed-citation publication-type="other" id="sref133">National Institutes of Health. A phase I clinical trial in 18&#x02012;60 adults (APICTH); c2020 [cited 2020 May 16th]. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct%202/show/NCT04313127" id="intref0055">https://clinicaltrials.gov/ct 2/show/NCT04313127</ext-link>.</mixed-citation></ref><ref id="bib134"><label>134</label><mixed-citation publication-type="other" id="sref134">National Institutes of Health. A study of a candidate COVID-19 vaccine (COV001); c2020 [cited 2020 May 16th]. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04324606" id="intref0060">https://clinicaltrials.gov/ct2/show/NCT04324606</ext-link>.</mixed-citation></ref><ref id="bib135"><label>135</label><mixed-citation publication-type="other" id="sref135">National Institutes of Health. Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) to prevent SARS-CoV-2 infection; c2020 [cited 2020 May 16th]. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04283461" id="intref0065">https://clinicaltrials.gov/ct2/show/NCT04283461</ext-link>.</mixed-citation></ref><ref id="bib136"><label>136</label><mixed-citation publication-type="other" id="sref136">National Institutes of Health. Study to describe the safety, tolerability, Immunogenicity, and potential efficacy of RNA vaccine candidates against COVID-19 in healthy adults; c2020 [cited 2020 May 16th]. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04368728" id="intref0070">https://clinicaltrials.gov/ct2/show/NCT04368728</ext-link>.</mixed-citation></ref><ref id="bib137"><label>137</label><mixed-citation publication-type="other" id="sref137">National Institutes of Health. Safety, Tolerability and immunogenicity of INO-4800 for COVID-19 in healthy volunteers; c2020 [cited 2020 May 16th]. Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04336410" id="intref0075">https://clinicaltrials.gov/ct2/show/NCT04336410</ext-link>.</mixed-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p>We acknowledge the financial support of the National Natural Science Foundation of China (No. 81925036), Special Funds for Prevention and Control of COVID-19 of Sichuan University (No. 0082604151018) and Zhejiang University special scientific research fund for COVID-19 prevention and control (No. 2020XG2X018).</p></ack></back></article>